Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 3	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 4	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 5	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 6	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 7	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 8	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 9	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 10	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 11	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 12	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 13	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 14	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 15	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 16	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 17	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 18	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 19	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 20	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 21	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 22	JUL 28	CA/CAplus patent coverage enhanced
NEWS 23	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 24	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 25	JUL 28	STN Viewer performance improved
NEWS 26	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items

```
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:32:56 ON 06 AUG 2008

=> file registry
COST IN U.S. DOLLARS                                 SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      0.21       0.21

FILE 'REGISTRY' ENTERED AT 09:33:33 ON 06 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    5 AUG 2008  HIGHEST RN 1038926-51-0
DICTIONARY FILE UPDATES:   5 AUG 2008  HIGHEST RN 1038926-51-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10530137\10530137a.str
```





```
chain nodes :
11  13
ring nodes :
1  2  3  4  5  6  7  8  9  10
chain bonds :
1-11  7-13
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10
exact/norm bonds :
1-11  5-7  6-10  7-8  7-13  8-9  9-10
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 :


G1:OH,SH

Match level :
```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 13:CLASS

L1   STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1   STR



G1 OH,SH

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 09:33:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   317 TO ITERATE

100.0% PROCESSED   317 ITERATIONS   22 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 5272 TO   7408
PROJECTED ANSWERS: 159 TO   721

L2   22 SEA SSS SAM L1

=> d scan

L2   22 ANSWERS   REGISTRY COPYRIGHT 2008 ACS on STN
IN   Acetamide, 2-[(2-aminoethyl)thio]-N-[2-[2-(3,4-dihydro-8-hydroxy-2,4-dioxo-
     1(2H)-quinazolinyl)ethoxy]phenyl]-
MF   C20 H22 N4 O5 S
CI   COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L2 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2,4(1H,3H)-Quinazolinedione, 1-[3-(3,5-dimethyl-1H-pyrazol-1-yl)propyl]-8-hydroxy-
MF C16 H18 N4 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2,4(1H,3H)-Quinazolinedione, 8-hydroxy-1-[4-(1H-imidazol-1-yl)butyl]-, hydrochloride (1:1)
MF C15 H16 N4 O3 . Cl H



● HCl

L2 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2,4(1H,3H)-Quinazolinedione, 1-[3-(5,6-dimethyl-1H-benzimidazol-1-yl)propyl]-8-hydroxy-, hydrochloride (1:1)
MF C20 H20 N4 O3 . Cl H



● HCl

L2 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2,4(1H,3H)-Quinazolinedione, 1-[3-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)propyl]-8-hydroxy-
MF C19 H17 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 full
FULL SEARCH INITIATED 09:35:31 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6545 TO ITERATE

100.0% PROCESSED 6545 ITERATIONS 572 ANSWERS
SEARCH TIME: 00.00.01

L3 572 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 179.28 179.49

FILE 'CAPLUS' ENTERED AT 09:35:35 ON 06 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 Aug 2008 VOL 149 ISS 6
FILE LAST UPDATED: 5 Aug 2008 (20080805/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> s l3
L4          126 L3

=> s l3 and (pd<=20021004 or ad<=20021004 or prd<=20021004)
            126 L3
       22845380 PD<=20021004
                  (PD<=20021004)
        4419692 AD<=20021004
                  (AD<=20021004)
        3887084 PRD<=20021004
                  (PRD<=20021004)
L5           77 L3 AND (PD<=20021004 OR AD<=20021004 OR PRD<=20021004)

=> log hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     7.32     186.81

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 09:36:51 ON 06 AUG 2008

Connecting via Winsock to STN



Welcome to STN International!  Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:
  * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 09:41:22 ON 06 AUG 2008
FILE 'CAPLUS' ENTERED AT 09:41:22 ON 06 AUG 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     7.32     186.81

=> file capus
'CAPUS' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'CAPLUS'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     7.32     186.81

FILE 'CAPLUS' ENTERED AT 09:41:38 ON 06 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
```

FILE COVERS 1907 - 6 Aug 2008 VOL 149 ISS 6
FILE LAST UPDATED: 5 Aug 2008 (20080805/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> d l3
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n

=> d l4

L4 ANSWER 1 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2008:674922 CAPLUS
DN 149:10043
TI Preparation of quinazolinone modulators of TGR5 for treatment of metabolic, cardiovascular and inflammatory diseases
IN Pinkerton, Anthony B.; Kabakibi, Ayman; Hoffman, Timothy Z.; Siegel, Dana L.; Noble, Stewart A.
PA Kalypsys, Inc., USA
SO PCT Int. Appl., 147pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008067219	A2	20080605	WO 2007-US85225	20071120
	WO 2008067219	A3	20080717		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRAI	US 2006-867783P	P	20061129		
	US 2007-975561P	P	20070927		
OS	MARPAT 149:10043				

=> d l5

L5 ANSWER 1 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN

```
AN   2004:513327  CAPLUS
DN   141:65136
TI   Method of using a COX-2 inhibitor and a TACE inhibitor as a combination
     therapy for the treatment of neoplasia, pain, inflammation, and
     vaso-occlusive events
IN   Masferrer, Jaime L.; Stephenson, Diane T.
PA   Pharmacia Corporation, USA
SO   U.S. Pat. Appl. Publ., 143 pp., Cont.-in-part of U.S. Ser. No. 868,063.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 21
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   --------
PI   US 20040120011      A1     20040624    US 2003-423526         20030425 <--
     EP 1522313          A1     20050413    EP 2004-26577          19991222 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI, RO, CY
     AU 2004201161       A1     20040422    AU 2004-201161         20040319 <--
     AU 2004201161       B2     20060209
     WO 2004096206       A2     20041111    WO 2004-US12620        20040423
     WO 2004096206       A3     20050407
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
             SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
             TD, TG
     AU 2004210578       A1     20041007    AU 2004-210578         20040910 <--
PRAI US 1998-113786P     P      19981223  <--
     US 1999-470951      B2     19991222  <--
     US 2001-868063      A2     20011005  <--
     US 1999-385214      A      19990827  <--
     AU 2000-25936       A3     19991222  <--
     AU 2000-27134       A3     19991222  <--
     EP 1999-968939      A3     19991222  <--
     US 2003-423526      A      20030425
OS   MARPAT 141:65136


=> d 15 1-77 ibib hitstr

L5   ANSWER 1 OF 77  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2004:513327  CAPLUS
DOCUMENT NUMBER:          141:65136
TITLE:                    Method of using a COX-2 inhibitor and a TACE inhibitor
                          as a combination therapy for the treatment of
                          neoplasia, pain, inflammation, and vaso-occlusive
                          events
INVENTOR(S):              Masferrer, Jaime L.; Stephenson, Diane T.
PATENT ASSIGNEE(S):       Pharmacia Corporation, USA
SOURCE:                   U.S. Pat. Appl. Publ., 143 pp., Cont.-in-part of U.S.
                          Ser. No. 868,063.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   21
```

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040122011	A1	20040624	US 2003-423526	20030425 <--
EP 1522313	A1	20050413	EP 2004-26577	19991222 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO, CY				
AU 2004201161	A1	20040422	AU 2004-201161	20040319 <--
AU 2004201161	B2	20060209		
WO 2004096206	A2	20041111	WO 2004-US12620	20040423
WO 2004096206	A3	20050407		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004210578	A1	20041007	AU 2004-210578	20040910 <--
PRIORITY APPLN. INFO.:			US 1998-113786P	P 19981223 <--
			US 1999-470951	B2 19991222 <--
			US 2001-868063	A2 20011005 <--
			US 1999-385214	A 19990827 <--
			AU 2000-25936	A3 19991222 <--
			AU 2000-27134	A3 19991222 <--
			EP 1999-968939	A3 19991222 <--
			US 2003-423526	A 20030425

OTHER SOURCE(S): MARPAT 141:65136

IT 204125-89-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(COX-2 inhibitor-TACE inhibitor combination for treatment of neoplasia, pain, inflammation, and vaso-occlusive events)

RN 204125-89-3 CAPLUS

CN L-Valinamide, (3R)-N2-[(3,4-dihydro-4-oxo-8-quinazolinyl)sulfonyl]-N-hydroxy-3-(2-methylpropyl)-L-α-asparaginyl-N,3-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 2 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:308423 CAPLUS
DOCUMENT NUMBER: 140:332510
TITLE: Neurologically active heterocyclic compounds, their preparation, and their therapeutic use
INVENTOR(S): Kok, Gaik Beng; Leung, Brenda Kwan Yi; Gautier, Elisabeth Colette Louise; Barnham, Kevin Jeffrey
PATENT ASSIGNEE(S): Prana Biotechnology Limited, Australia
SOURCE: PCT Int. Appl., 183 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031161	A1	20040415	WO 2003-AU1303	20031003 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2500952	A1	20040415	CA 2003-2500952	20031003 <--
AU 2003265740	A1	20040423	AU 2003-265740	20031003 <--
EP 1558585	A1	20050803	EP 2003-798831	20031003 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015008	A	20050809	BR 2003-15008	20031003 <--
CN 1720238	A	20060111	CN 2003-80105290	20031003 <--
JP 2006508929	T	20060316	JP 2004-540379	20031003 <--
NZ 539211	A	20080530	NZ 2003-539211	20031003 <--
IN 2005KN00785	A	20060609	IN 2005-KN785	20050502 <--
US 20060167000	A1	20060727	US 2005-530137	20051003 <--
PRIORITY APPLN. INFO.:			AU 2002-951864 A	20021004 <--
			AU 2002-951865 A	20021004 <--

AU 2002-951866 A 20021004 <--
AU 2002-951868 A 20021004 <--
WO 2003-AU1303 W 20031003

OTHER SOURCE(S): MARPAT 140:332510

IT 679797-49-0P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(neurol. active heterocyclic compds., preparation, and therapeutic use)

RN 679797-49-0 CAPLUS

CN 4(3H)-Quinazolinone, 5,7-dichloro-3-cyclopropyl-8-hydroxy- (CA INDEX NAME)



IT 679797-48-9P 679797-50-3P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(neurol. active heterocyclic compds., preparation, and therapeutic use)

RN 679797-48-9 CAPLUS

CN 4(3H)-Quinazolinone, 5,7-dichloro-3-(4-fluorophenyl)-8-hydroxy- (CA INDEX NAME)



RN 679797-50-3 CAPLUS

CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy- (CA INDEX NAME)



IT 16064-17-8
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neurol. active heterocyclic compds., preparation, and therapeutic use)

RN 16064-17-8 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy- (CA INDEX NAME)



IT 16064-17-8D, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neurol. active heterocyclic compds., preparation, and therapeutic use)
RN 16064-17-8 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:1006962 CAPLUS
DOCUMENT NUMBER: 140:59652
TITLE: Preparation of fused-ring pyrimidin-4(3H)-one derivatives as LXR modulators
INVENTOR(S): Kaneko, Satoru; Watanabe, Tsuyoshi; Oda, Kozo; Mohan, Raju; Schweiger, Edwin J.; Martin, Richard
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan; X-Ceptor Therapeutics, Inc.
SOURCE: PCT Int. Appl., 465 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003106435	A1	20031224	WO 2003-JP7677	20030617 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003238157 A1 20031231 AU 2003-238157 20030617 <--
PRIORITY APPLN. INFO.: US 2002-389662P P 20020618 <--
WO 2003-JP7677 W 20030617

OTHER SOURCE(S): MARPAT 140:59652
IT 637345-58-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused-ring pyrimidin-4(3H)-one derivs. as LXR modulators)
RN 637345-58-5 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-(phenylmethyl)-3-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:162214 CAPLUS
DOCUMENT NUMBER: 139:127325
TITLE: Development of a high-throughput screening-amenable assay for human poly(ADP-ribose) polymerase inhibitors
AUTHOR(S): Brown, Janice A.; Marala, Ravi B.
CORPORATE SOURCE: Pfizer Global Research and Development, Department of Cardiovascular and Metabolic Diseases, Pfizer Inc., Groton, CT, 06340, USA
SOURCE: Journal of Pharmacological and Toxicological Methods (2002), 47(3), 137-141
CODEN: JPTMEZ; ISSN: 1056-8719
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 90417-38-2, NU-1025
RL: ANT (Analyte); PAC (Pharmacological activity); ANST (Analytical study); BIOL (Biological study)
(development of high-throughput screening-amenable assay for human poly(ADP-ribose) polymerase inhibitors)
RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:775927 CAPLUS
DOCUMENT NUMBER: 138:85461
TITLE: Functional characterization of the poly(ADP-ribose) polymerase activity of tankyrase 1, a potential regulator of telomere length
AUTHOR(S): Rippmann, Jorg F.; Damm, Klaus; Schnapp, Andreas
CORPORATE SOURCE: Department of Oncology Research, Boehringer Ingelheim Pharma KG, Biberach, 88397, Germany
SOURCE: Journal of Molecular Biology (2002), 323(2), 217-224
CODEN: JMOBAK; ISSN: 0022-2836
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 90417-38-2, Nu 1025
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(poly(ADP-ribose) polymerase activity of tankyrase 1 regulates telomere length and catalyzes auto(ADP-ribosyl)ation reaction as well as modification of TRF 1/2)
RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:219523 CAPLUS
DOCUMENT NUMBER: 137:103519
TITLE: Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site
AUTHOR(S): Tentori, Lucio; Leonetti, Carlo; Scarsella, Marco; D'Amati, Giulia; Portarena, Ilaria; Zupi, Gabriella; Bonmassar, Enzo; Graziani, Grazia
CORPORATE SOURCE: Department of Neuroscience, University of Rome Tor

Vergata, Rome, 00133, Italy
SOURCE: Blood (2002), 99(6), 2241-2244
CODEN: BLOOAW; ISSN: 0006-4971
PUBLISHER: American Society of Hematology
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 90417-38-2, NU1025
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combined treatment with temozolomide and PARP inhibitor enhances survival of mice bearing hematol. malignancy at central nervous system site)
RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:130805 CAPLUS
DOCUMENT NUMBER: 137:379712
TITLE: Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes
AUTHOR(S): Tentori, Lucio; Portarena, Ilaria; Vernole, Patrizia; Gold, Barry; Graziani, Grazia
CORPORATE SOURCE: Department of Neuroscience, University of Rome "Tor Vergata", Rome, 00133, Italy
SOURCE: Cancer Chemotherapy and Pharmacology (2002), 49(3), 217-224
CODEN: CCPHDZ; ISSN: 0344-5704
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 90417-38-2, NU1025
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(apoptotic and genotoxic effects of a Me sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes)
RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:23848 CAPLUS
DOCUMENT NUMBER: 136:85820
TITLE: Preparation of quinazolines and quinazolinones as neuropeptide Y receptor antagonists for treatment of obesity and circulatory disorders
INVENTOR(S): Carpino, Philip A.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 24 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 6337332	B1	20020108	US 1999-382418		19990824 <--
PRIORITY APPLN. INFO.:			US 1998-100749P	P	19980917 <--

OTHER SOURCE(S): MARPAT 136:85820
IT 387346-82-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinazolines and quinazolinones as neuropeptide Y receptor antagonists for treatment of obesity and circulatory disorders)
RN 387346-82-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-(4-chlorophenyl)ethenyl]-8-hydroxy-3-[3-[1-(2-phenylethyl)-4-piperidinyl]propyl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:752372 CAPLUS
DOCUMENT NUMBER: 136:31304
TITLE: Modeling of Poly(ADP-ribose)polymerase (PARP) Inhibitors. Docking of Ligands and Quantitative Structure-Activity Relationship Analysis
AUTHOR(S): Costantino, Gabriele; Macchiarulo, Antonio; Camaioni, Emidio; Pellicciari, Roberto
CORPORATE SOURCE: Dipartimento di Chimica e Tecnologia del Farmaco, Universita di Perugia, Perugia, 06127, Italy
SOURCE: Journal of Medicinal Chemistry (2001), 44(23), 3786-3794
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

IT 90417-38-2, Nu 1025 114882-07-4 172462-88-3
211172-81-5 211172-82-6
RL: DMA (Drug mechanism of action); PRP (Properties); BIOL (Biological study)
(modeling of poly(ADP-ribose)polymerase (PARP) inhibitors in relation to docking of ligands and quant. structure-activity relationship anal.)

RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



RN 114882-07-4 CAPLUS
CN 4(1H)-Quinazolinone, 8-hydroxy-2-phenyl- (9CI) (CA INDEX NAME)



RN 172462-88-3 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-(4-nitrophenyl)- (CA INDEX NAME)



RN 211172-81-5 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 211172-82-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-(4-aminophenyl)-8-hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:324241 CAPLUS
DOCUMENT NUMBER: 136:144750
TITLE: Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components
AUTHOR(S): Tentori, Lucio; Portarena, Ilaria; Vernole, Patrizia; De Fabritiis, Paolo; Madaio, Raffaele; Balduzzi, Alessandra; Roy, Rabindra; Bonmassar, Enzo; Graziani, Grazia
CORPORATE SOURCE: Department of Neuroscience, Section of Pharmacology and Medical Oncology, Via di Tor Vergata 135, University of Rome "Tor Vergata", Rome, 00133, Italy
SOURCE: Cancer Chemotherapy and Pharmacology (2001), 47(4), 361-369
CODEN: CCPHDZ; ISSN: 0344-5704
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 90417-38-2, NU1025
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors)
RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:228868 CAPLUS
DOCUMENT NUMBER: 134:252356
TITLE: Preparation of 2-(arylamino)-4-quinazolinols as inhibitors of cleavage of protein substrates by caspase-3
INVENTOR(S): Jacobs, Robert Toms; Folmer, James; Simpson, Thomas Richard; Chaudhari, Bipinchandra; Frazee, William Jackson; Davenport, Timothy Wayne
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021598	A1	20010329	WO 2000-GB3555	20000918 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1218358	A1	20020703	EP 2000-958907	20000918 <--
EP 1218358	B1	20060913		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003509501	T	20030311	JP 2001-524977	20000918 <--
AT 339406	T	20061015	AT 2000-958907	20000918 <--
ES 2270867	T3	20070416	ES 2000-958907	20000918 <--
US 6399603	B1	20020604	US 2000-668322	20000922 <--
PRIORITY APPLN. INFO.:			US 1999-155623P P	19990923 <--
			WO 2000-GB3555 W	20000918 <--

OTHER SOURCE(S): MARPAT 134:252356
IT 331641-62-4P 331641-65-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-(arylamino)-4-quinazolinols as inhibitors of cleavage of protein substrates by caspase-3)
RN 331641-62-4 CAPLUS
CN 8-Quinazolinesulfonamide, 6-chloro-2-[(3,4-dichlorophenyl)amino]-N-[(4-

fluorophenyl)methyl]-1,4-dihydro-4-oxo- (CA INDEX NAME)



RN 331641-65-7 CAPLUS
CN 8-Quinazolinesulfonamide, 6-chloro-N-[(4-fluorophenyl)methyl]-1,4-dihydro-4-oxo-2-[[4-(trifluoromethyl)phenyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:185074 CAPLUS
DOCUMENT NUMBER: 134:222727
TITLE: Preparation of tetrahydroquinazoline-2,4-diones for inhibiting serotonin reuptake or 5-HT2A serotonin receptor binding
INVENTOR(S): Butler, Todd William; Fliri, Anton Franz Josef; Gallaschun, Randall James; Jones, Brian Patrick; Ragan, John Anthony
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 35 pp.

CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
EP 1083178	A1	20010314	EP 2000-307433	20000830	<--
EP 1083178	B1	20040915			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
US 6521630	B1	20030218	US 2000-650486	20000829	<--
JP 2001114778	A	20010424	JP 2000-261115	20000830	<--
JP 3285343	B2	20020527			
AT 276261	T	20041015	AT 2000-307433	20000830	<--
PT 1083178	T	20041231	PT 2000-307433	20000830	<--
ES 2226726	T3	20050401	ES 2000-307433	20000830	<--
JP 2002212161	A	20020731	JP 2001-337442	20011102	<--
JP 3727569	B2	20051214			
US 20030109516	A1	20030612	US 2003-340287	20030110	<--
PRIORITY APPLN. INFO.:			US 1999-151725P	P 19990831	<--
			US 2000-650486	A3 20000829	<--
			JP 2000-261115	A3 20000830	<--

OTHER SOURCE(S): MARPAT 134:222727
IT 329790-30-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydroquinazoline-2,4-diones for inhibiting serotonin reuptake or 5-HT2A serotonin receptor binding)
RN 329790-30-9 CAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 3-[3-[4-(4-chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]propyl]-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:98155 CAPLUS
DOCUMENT NUMBER: 135:102100
TITLE: Differential effects of the poly(ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro
AUTHOR(S): Bowman, K. J.; Newell, D. R.; Calvert, A. H.; Curtin, N. J.
CORPORATE SOURCE: Cancer Research Unit, University of Newcastle upon

Tyne Medical School, Newcastle upon Tyne, NE2 4HH, UK
SOURCE: British Journal of Cancer (2001), 84(1), 106-112
CODEN: BJCAAI; ISSN: 0007-0920
PUBLISHER: Harcourt Publishers Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 90417-38-2, NU 1025
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(poly(ADP-ribose) polymerase inhibitor NU 1025 differential effects on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro)
RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:573476 CAPLUS
DOCUMENT NUMBER: 134:36742
TITLE: Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines
AUTHOR(S): Delaney, Carol A.; Wang, Lan-Z.; Kyle, Suzanne; White, Alex W.; Calvert, A. Hilary; Curtin, Nicola J.; Durkacz, Barbara W.; Hostomsky, Zdenek; Newell, David R.
CORPORATE SOURCE: Cancer Research Unit, Medical School, University of Newcastle upon Tyne, Newcastle upon Tyne, NE2 4HH, UK
SOURCE: Clinical Cancer Research (2000), 6(7), 2860-2867
CODEN: CCREF4; ISSN: 1078-0432
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 90417-38-2, NU1025
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by poly(adenosine diphosphoribose) polymerase inhibitors in human tumor cell lines)
RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:12973 CAPLUS
DOCUMENT NUMBER: 132:30325
TITLE: New α-Substituted Succinate-Based Hydroxamic Acids as TNFα Convertase Inhibitors
AUTHOR(S): Barlaam, Bernard; Bird, T. Geoffrey; Lambert-van der Brempt, Christine; Campbell, Douglas; Foster, Steve J.; Maciewicz, Rose
CORPORATE SOURCE: Centre de Recherches, AstraZeneca Zeneca Pharma, Reims, 51689, Fr.
SOURCE: Journal of Medicinal Chemistry (1999), 42(23), 4890-4908
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 204125-89-3P
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(new α-substituted succinate-based hydroxamic acids as TNFα convertase inhibitors)
RN 204125-89-3 CAPLUS
CN L-Valinamide, (3R)-N2-[(3,4-dihydro-4-oxo-8-quinazolinyl)sulfonyl]-N-hydroxy-3-(2-methylpropyl)-L-α-asparaginyl-N,3-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



IT 204126-41-0P 204126-43-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(new α-substituted succinate-based hydroxamic acids as TNFα convertase inhibitors)
RN 204126-41-0 CAPLUS
CN L-Valinamide, (3R)-N-[(1,4-dihydro-4-oxo-8-quinazolinyl)sulfonyl]-3-(2-methylpropyl)-L-β-asparty1-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204126-43-2 CAPLUS
CN L-Valinamide, (3R)-N-[(1,4-dihydro-4-oxo-8-quinazolinyl)sulfonyl]-3-(2-methylpropyl)-L-β-asparty1-N,3-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:571811 CAPLUS
DOCUMENT NUMBER: 131:214292
TITLE: 2- or 3-(Substituted aminoalkoxyphenyl)quinazolin-4-

ones useful as partial estrogen agonists
INVENTOR(S): Koko, Marci Catherine; Santilli, Arthur Attilio
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: U.S., 9 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 5948775	A	19990907	US 1998-41184		19980312 <--
PRIORITY APPLN. INFO.:			US 1997-41088P	P	19970319 <--

OTHER SOURCE(S): MARPAT 131:214292
IT 242478-06-4P, 2-[4-(2-Chloroethoxy)phenyl]-8-hydroxy-3-(4-hydroxyphenyl)-3H-quinazolin-4-one 242478-11-1P, 3-[4-(2-Chloroethoxy)phenyl]-8-hydroxy-2-(4-hydroxyphenyl)-3H-quinazolin-4-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of (aminoalkoxyphenyl)quinazolinones partial estrogen agonists)
RN 242478-06-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[4-(2-chloroethoxy)phenyl]-8-hydroxy-3-(4-hydroxyphenyl)- (CA INDEX NAME)





RN 242478-11-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-[4-(2-chloroethoxy)phenyl]-8-hydroxy-2-(4-hydroxyphenyl)- (CA INDEX NAME)





IT 242478-07-5P, 8-Hydroxy-3-(4-hydroxyphenyl)-2-[4-[2-(piperidin-1-yl)ethoxy]phenyl]-3H-quinazolin-4-one 242478-12-2P, 8-Hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidin-1-ylethoxy)phenyl]-3H-quinazolin-4-one
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of (aminoalkoxyphenyl)quinazolinones partial estrogen agonists)

RN 242478-07-5 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-3-(4-hydroxyphenyl)-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 242478-12-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-(4-hydroxyphenyl)-3-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:151351 CAPLUS
DOCUMENT NUMBER: 130:306182
TITLE: Interactive effects of inhibitors of poly (ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage
AUTHOR(S): Boulton, Sallyanne; Kyle, Suzanne; Durkacz, Barbara W.
CORPORATE SOURCE: Cancer Research Unit, Medical School, University of Newcastle upon Tyne, Newcastle upon Tyne, NE2 4HH, UK
SOURCE: Carcinogenesis (1999), 20(2), 199-203
CODEN: CRNGDP; ISSN: 0143-3334
PUBLISHER: Oxford University Press
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 90417-38-2, NU1025
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on DNA damage and cytotoxicity induced by ionizing radiation and temozolomide in relation to DNA repair inhibition)
RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:761616 CAPLUS

DOCUMENT NUMBER: 130:177204
TITLE: Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064
AUTHOR(S): Bowman, K. J.; White, A.; Golding, B. T.; Griffin, R. J.; Curtin, N. J.
CORPORATE SOURCE: Cancer Research Unit, University of Newcastle upon Tyne, Medical School, Newcastle upon Tyne, NE2 4HH, UK
SOURCE: British Journal of Cancer (1998), 78(10), 1269-1277
CODEN: BJCAAI; ISSN: 0007-0920
PUBLISHER: Churchill Livingstone
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 90417-38-2, NU1025
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(potentiation of anticancer cytotoxicity by poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064)
RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:756610 CAPLUS
DOCUMENT NUMBER: 130:133636
TITLE: Resistance-Modifying Agents. 5. Synthesis and Biological Properties of Quinazolinone Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase (PARP)
AUTHOR(S): Griffin, Roger J.; Srinivasan, Sheila; Bowman, Karen; Calvert, A. Hilary; Curtin, Nicola J.; Newell, David R.; Pemberton, Louise C.; Golding, Bernard T.
CORPORATE SOURCE: Department of Chemistry, The University of Newcastle upon Tyne, Newcastle upon Tyne, NE1 7RU, UK
SOURCE: Journal of Medicinal Chemistry (1998), 41(26), 5247-5256
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 90417-38-2P 114882-07-4P 211172-79-1P 211172-81-5P 211172-82-6P 211172-84-8P 220115-32-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and cytotoxicity-potentiating activity of quinazolinone inhibitors of DNA repair involving poly(ADP-ribose) polymerase)

RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



RN 114882-07-4 CAPLUS
CN 4(1H)-Quinazolinone, 8-hydroxy-2-phenyl- (9CI) (CA INDEX NAME)



RN 211172-79-1 CAPLUS
CN Benzonitrile, 4-(3,4-dihydro-8-hydroxy-4-oxo-2-quinazolinyl)- (CA INDEX NAME)



RN 211172-81-5 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 211172-82-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-(4-aminophenyl)-8-hydroxy- (CA INDEX NAME)



RN 211172-84-8 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 220115-32-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-(4-methylphenyl)- (CA INDEX NAME)



IT 172462-88-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and reaction of; preparation and cytotoxicity-potentiating activity
of quinazolinone inhibitors of DNA repair involving poly(ADP-ribose) polymerase)
RN 172462-88-3 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-(4-nitrophenyl)- (CA INDEX NAME)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:543074 CAPLUS
DOCUMENT NUMBER: 129:161571
ORIGINAL REFERENCE NO.: 129:32883a,32886a
TITLE: Preparation of quinazolinone phosphates as prodrugs for inhibitors of poly ADP-ribosyltransferase.
INVENTOR(S): Griffin, Roger John; Calvert, Alan Hilary; Curtin, Nicola Jane; Newell, David Richard; Golding, Bernard Thomas
PATENT ASSIGNEE(S): Newcastle University Ventures Limited, UK
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9833802	A1	19980806	WO 1998-GB303	19980130 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2278290	A1	19980806	CA 1998-2278290	19980130 <--
CA 2278290	C	20050510		
AU 9858739	A	19980825	AU 1998-58739	19980130 <--
EP 966476	A1	19991229	EP 1998-902115	19980130 <--
EP 966476	B1	20020904		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001511776	T	20010814	JP 1998-532644	19980130 <--
AT 223424	T	20020915	AT 1998-902115	19980130 <--
MX 9907042	A	20000531	MX 1999-7042	19990729 <--
US 6156739	A	20001205	US 1999-362901	19990729 <--
PRIORITY APPLN. INFO.:			GB 1997-2701 A	19970201 <--
			WO 1998-GB303 W	19980130 <--

OTHER SOURCE(S): MARPAT 129:161571
IT 90417-38-2P 99071-94-0P 114882-07-4P
172462-88-3P 211172-79-1P 211172-81-5P
211172-82-6P 211172-84-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinazolinone phosphates as prodrugs for inhibitors of poly ADP-ribosyltransferase)
RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



RN 99071-94-0 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2,3-dimethyl- (CA INDEX NAME)



RN 114882-07-4 CAPLUS
CN 4(1H)-Quinazolinone, 8-hydroxy-2-phenyl- (9CI) (CA INDEX NAME)



RN 172462-88-3 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-(4-nitrophenyl)- (CA INDEX NAME)



RN 211172-79-1 CAPLUS
CN Benzonitrile, 4-(3,4-dihydro-8-hydroxy-4-oxo-2-quinazolinyl)- (CA INDEX NAME)



RN 211172-81-5 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 211172-82-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-(4-aminophenyl)-8-hydroxy- (CA INDEX NAME)



RN 211172-84-8 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:161082 CAPLUS
DOCUMENT NUMBER: 128:205148
ORIGINAL REFERENCE NO.: 128:40583a,40584a
TITLE: Preparation of peptide sulfonamides as inhibitors of

tumor necrosis factor
INVENTOR(S): Barlaam, Bernard Christophe
PATENT ASSIGNEE(S): Zeneca Limited, Fr.
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9807742	A1	19980226	WO 1997-GB2222	19970819 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9740217	A	19980306	AU 1997-40217	19970819 <--
ZA 9707580	A	19990217	ZA 1997-7580	19970822 <--
IN 1997DE02389	A	20050311	IN 1997-DE2389	19970822 <--
PRIORITY APPLN. INFO.:			FR 1996-1815 A	19960823 <--
			FR 1996-2031 A	19960925 <--
			EP 1996-401815 A	19960823 <--
			EP 1996-402031 A	19960925 <--
			WO 1997-GB2222 W	19970819 <--

OTHER SOURCE(S): MARPAT 128:205148
IT 204125-89-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide sulfonamides as inhibitors of tumor necrosis factor)
RN 204125-89-3 CAPLUS
CN L-Valinamide, (3R)-N2-[(3,4-dihydro-4-oxo-8-quinazolinyl)sulfonyl]-N-hydroxy-3-(2-methylpropyl)-L-α-asparaginyl-N,3-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



IT 204126-41-0P 204126-43-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of peptide sulfonamides as inhibitors of tumor necrosis factor)

RN 204126-41-0 CAPLUS
CN L-Valinamide, (3R)-N-[(1,4-dihydro-4-oxo-8-quinazolinyl)sulfonyl]-3-(2-methylpropyl)-L-β-asparty1-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204126-43-2 CAPLUS
CN L-Valinamide, (3R)-N-[(1,4-dihydro-4-oxo-8-quinazolinyl)sulfonyl]-3-(2-methylpropyl)-L-β-asparty1-N,3-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:129634 CAPLUS
DOCUMENT NUMBER: 128:280137
ORIGINAL REFERENCE NO.: 128:55389a,55392a
TITLE: Inhibitor and NAD+ Binding to Poly(ADP-ribose) Polymerase As Derived from Crystal Structures and Homology Modeling

AUTHOR(S): Ruf, Armin; de Murcia, Gilbert; Schulz, Georg E.
CORPORATE SOURCE: Institut fuer Organische Chemie und Biochemie, Freiburg, D-79104, Germany
SOURCE: Biochemistry (1998), 37(11), 3893-3900
CODEN: BICHAW; ISSN: 0006-2960
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 90417-38-2, NU1025
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homol. modeling)
RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



IT 90417-38-2D, NU1025, complexes with poly(ADP-ribose) polymerase
RL: PRP (Properties)
(inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homol. modeling)
RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:685969 CAPLUS
DOCUMENT NUMBER: 127:341480
ORIGINAL REFERENCE NO.: 127:66875a,66878a
TITLE: Low nicotinamide mononucleotide adenylyltransferase activity in a tiazofurin-resistant cell line: effects on NAD metabolism and DNA repair
AUTHOR(S): Boulton, S.; Kyle, S.; Durkacz, B. W.
CORPORATE SOURCE: Cancer Research Unit, Medical School, University of Newcastle upon Tyne, Newcastle upon Tyne, NE2 4HH, UK
SOURCE: British Journal of Cancer (1997), 76(7), 845-851
CODEN: BJCAAI; ISSN: 0007-0920
PUBLISHER: Churchill Livingstone

DOCUMENT TYPE: Journal
LANGUAGE: English
IT 90417-38-2, NU1025
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(low NMN adenylyltransferase activity in a tiazofurin-resistant cell line and effects on NAD metabolism and DNA repair in relation to sensitization to alkylating agents and poly(ADP-ribose) polymerase inhibitors)
RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 24 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:495795 CAPLUS
DOCUMENT NUMBER: 125:189126
ORIGINAL REFERENCE NO.: 125:35267a,35270a
TITLE: Resistance modifying agents. 3. Novel benzimidazole and quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase
AUTHOR(S): Griffin, Roger J.; Srinivasan, Sheila; White, Alex W.; Bowman, Karen; Calvert, A. Hilary; Curtin, Nicola J.; Newell, David R.; Golding, Bernard T.
CORPORATE SOURCE: Dep. Chem., Univ. Newcastle, Newcastle upon Tyne, NE1 7RU, UK
SOURCE: Pharmaceutical Sciences (1996), 2(1), 43-47
CODEN: PHSCFB; ISSN: 1356-6881
PUBLISHER: Royal Pharmaceutical Society of Great Britain
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 125:189126
IT 90417-38-2P 114882-07-4P 172462-88-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(resistance modifying agents. 3. Novel benzimidazole and quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase)
RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



RN 114882-07-4 CAPLUS
CN 4(1H)-Quinazolinone, 8-hydroxy-2-phenyl- (9CI) (CA INDEX NAME)



RN 172462-88-3 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-(4-nitrophenyl)- (CA INDEX NAME)



L5 ANSWER 25 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:994887 CAPLUS
DOCUMENT NUMBER: 124:86997
ORIGINAL REFERENCE NO.: 124:16351a,16354a
TITLE: Preparation of benzamide analogs as poly(ADP-ribose) polymerase inhibitors
INVENTOR(S): Griffin, Roger John; Calvert, Alan Hilary; Curtin, Nicola Jane; Newell, David Richard; Golding, Bernard Thomas
PATENT ASSIGNEE(S): Cancer Research Campaign Technology Ltd., UK
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9524379	A1	19950914	WO 1995-GB513	19950309 <--

W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG,

MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA

RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

CA 2184747	A1	19950914	CA 1995-2184747	19950309 <--
CA 2184747	C	20031014		
CA 2350941	A1	19950914	CA 1995-2350941	19950309 <--
CA 2352592	A1	19950914	CA 1995-2352592	19950309 <--
CA 2352592	C	20060606		
AU 9518565	A	19950925	AU 1995-18565	19950309 <--
AU 693167	B2	19980625		
EP 749415	A1	19961227	EP 1995-910653	19950309 <--
EP 749415	B1	19990908		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1143358	A	19970219	CN 1995-192011	19950309 <--
CN 1081624	C	20020327		
JP 09510704	T	19971028	JP 1995-523316	19950309 <--
EP 879820	A1	19981125	EP 1998-202102	19950309 <--
EP 879820	B1	20011212		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
EP 897915	A1	19990224	EP 1998-202103	19950309 <--
EP 897915	B1	20030122		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
AT 184271	T	19990915	AT 1995-910653	19950309 <--
ES 2135707	T3	19991101	ES 1995-910653	19950309 <--
AT 210651	T	20011215	AT 1998-202102	19950309 <--
PT 879820	T	20020628	PT 1998-202102	19950309 <--
ES 2169472	T3	20020701	ES 1998-202102	19950309 <--
AT 231494	T	20030215	AT 1998-202103	19950309 <--
US 5756510	A	19980526	US 1996-706326	19960830 <--
US 6015827	A	20000118	US 1998-56928	19980408 <--
GR 3031886	T3	20000229	GR 1999-402976	19991118 <--
US 6316455	B1	20011113	US 1999-448485	19991124 <--

PRIORITY APPLN. INFO.:	GB 1994-4485	A	19940309 <--
	CA 1995-2184747	A3	19950309 <--
	EP 1995-910653	A3	19950309 <--
	WO 1995-GB513	W	19950309 <--
	US 1996-706326	A3	19960830 <--
	US 1998-56928	A3	19980408 <--

OTHER SOURCE(S): MARPAT 124:86997

IT 16064-17-8P 90417-38-2P 114882-07-4P 172462-88-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzamide analogs as poly(ADP-ribose) polymerase inhibitors)

RN 16064-17-8 CAPLUS

CN 4(3H)-Quinazolinone, 8-hydroxy- (CA INDEX NAME)



RN 90417-38-2 CAPLUS

CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



RN 114882-07-4 CAPLUS
CN 4(1H)-Quinazolinone, 8-hydroxy-2-phenyl- (9CI) (CA INDEX NAME)



RN 172462-88-3 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-(4-nitrophenyl)- (CA INDEX NAME)



L5 ANSWER 26 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:936639 CAPLUS
DOCUMENT NUMBER: 124:21046
ORIGINAL REFERENCE NO.: 124:3819a,3822a
TITLE: Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)
AUTHOR(S): Griffin, Roger J.; Pemberton, Louise C.; Rhodes, Darren; Bleasdale, Christine; Bowman, Karen; Calvert, A. Hilary; Curtin, Nicola J.; Durkacz, Barbara W.; Newell, David R.; et al.
CORPORATE SOURCE: Medical School, University of Newcastle, Newcastle upon Tyne, NE2 4HH, UK
SOURCE: Anti-Cancer Drug Design (1995), 10(6), 507-14
CODEN: ACDDEA; ISSN: 0266-9536
PUBLISHER: Oxford University Press
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 90417-38-2 99071-94-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); PRP (Properties); BIOL (Biological study)
(inhibitors of DNA repair enzyme poly(ADP-ribose) polymerase)
RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



RN 99071-94-0 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2,3-dimethyl- (CA INDEX NAME)



L5 ANSWER 27 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:936063 CAPLUS
DOCUMENT NUMBER: 124:44782
ORIGINAL REFERENCE NO.: 124:8187a,8190a
TITLE: Potentiation of temozolomide-induced cytotoxicity: A comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors
AUTHOR(S): Boulton, S.; Pemberton, L C.; Porteous, J K.; Curtin, N J.; Griffin, R J.; Golding, B T.; Durkacz, B W.
CORPORATE SOURCE: Cancer Research Unit, University, Newcastle upon Tyne, NE2 4HH, UK
SOURCE: British Journal of Cancer (1995), 72(4), 849-56
CODEN: BJCAAI; ISSN: 0007-0920
PUBLISHER: Macmillan Scientific & Medical Division
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 90417-38-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(potentiation of temozolomide-induced cytotoxicity: a comparative study of the biol. effects of poly(ADP-ribose) polymerase inhibitors)
RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



L5 ANSWER 28 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:841957 CAPLUS
DOCUMENT NUMBER: 123:339482
ORIGINAL REFERENCE NO.: 123:60927a,60930a
TITLE: Synthesis of boxazomycin B and related analogs
AUTHOR(S): Suto, Mark J.; Turner, William R.
CORPORATE SOURCE: Parke-Davis Pharm. Res. Div., Warner Lambert Co., Ann Arbor, MI, 48105, USA
SOURCE: Tetrahedron Letters (1995), 36(40), 7213-16
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 123:339482
IT 171010-60-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of boxazomycin B and analogs)
RN 171010-60-9 CAPLUS
CN 4(3H)-Quinazolinone, 5,8-dihydroxy-2-(5-methoxy-2-methyl-4-pyrimidinyl)-7-methyl- (CA INDEX NAME)



L5 ANSWER 29 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:794874 CAPLUS
DOCUMENT NUMBER: 123:285807
ORIGINAL REFERENCE NO.: 123:51215a,51218a
TITLE: Preparation of heterocyclic compounds as bradykinin antagonists.
INVENTOR(S): Oku, Teruo; Kayakiri, Hiroshi; Satoh, Shigeki; Abe, Yoshito; Sawada, Yuki; Inoue, Takayuki; Tanaka, Hirokazu
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 123 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 622361	A1	19941102	EP 1994-106486	19940426 <--
EP 622361	B1	20011004		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AU 9460525	A	19941103	AU 1994-60525	19940419 <--
AU 680870	B2	19970814		
ZA 9402780	A	19950109	ZA 1994-2780	19940421 <--
IL 109395	A	19980924	IL 1994-109395	19940422 <--
RU 2135478	C1	19990827	RU 1994-13439	19940422 <--
CA 2122236	A1	19941029	CA 1994-2122236	19940426 <--
CA 2122236	C	20070213		
JP 07002780	A	19950106	JP 1994-88897	19940426 <--
JP 3346437	B2	20021118		
US 5563162	A	19961008	US 1994-233771	19940426 <--
AT 206412	T	20011015	AT 1994-106486	19940426 <--
ES 2161231	T3	20011201	ES 1994-106486	19940426 <--
PT 622361	T	20020328	PT 1994-106486	19940426 <--
CN 1097417	A	19950118	CN 1994-105013	19940427 <--
CN 1043344	C	19990512		
HU 70493	A2	19951030	HU 1994-1221	19940427 <--
HU 223140	B1	20040329		
TW 381081	B	20000201	TW 1994-83103786	19940427 <--
US 5708173	A	19980113	US 1996-660393	19960607 <--
US 5922711	A	19990713	US 1997-933354	19970919 <--
US 6169095	B1	20010102	US 1999-228973	19990112 <--
PRIORITY APPLN. INFO.:			GB 1993-8804 A	19930428 <--
			GB 1993-18929 A	19930913 <--
			US 1994-233771 A3	19940426 <--
			US 1996-660393 A3	19960607 <--
			US 1997-933354 A1	19970919 <--

OTHER SOURCE(S): MARPAT 123:285807

IT 90417-38-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterocyclic compds. as bradykinin antagonists.)

RN 90417-38-2 CAPLUS

CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



L5 ANSWER 30 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:408661 CAPLUS

DOCUMENT NUMBER: 122:251995

ORIGINAL REFERENCE NO.: 122:45761a,45764a

TITLE: Quinazoline-containing developer composition for processing black-and-white photographic material

INVENTOR(S): Kato, Mariko; Ishikawa, Wataru; Sanpei, Takeshi

PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06324437	A	19941125	JP 1993-113107	19930514 <--

PRIORITY APPLN. INFO.: JP 1993-113107 19930514 <--
OTHER SOURCE(S): MARPAT 122:251995
IT 162223-20-3
RL: NUU (Other use, unclassified); USES (Uses)
(quinazoline-containing developer composition for processing black-and-white photog. material)
RN 162223-20-3 CAPLUS
CN 4(3H)-Quinazolinone, 8-mercapto-2-methyl- (CA INDEX NAME)



L5 ANSWER 31 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:655816 CAPLUS
DOCUMENT NUMBER: 121:255816
ORIGINAL REFERENCE NO.: 121:46703a,46706a
TITLE: preparation of 1-aryl-3-(3,4-dihydro-4-oxo-3-quinazolinyl)urea fungicidal agents
INVENTOR(S): Takasugi, James Jan; Neypes, Millord Victor Ty; Evans, Lynn Susan; Kohls, Clint Louis; Witucki, Laurie Ann
PATENT ASSIGNEE(S): American Cyanamid Co., USA
SOURCE: Eur. Pat. Appl., 43 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 572782	A1	19931208	EP 1993-106107	19930415 <--
EP 572782	B1	19960626		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5276038	A	19940104	US 1992-891528	19920601 <--
AT 139770	T	19960715	AT 1993-106107	19930415 <--
ES 2088607	T3	19960816	ES 1993-106107	19930415 <--
JP 06056798	A	19940301	JP 1993-147029	19930526 <--
CA 2097276	A1	19931202	CA 1993-2097276	19930528 <--
ZA 9303793	A	19931222	ZA 1993-3793	19930528 <--
HU 65219	A2	19940502	HU 1993-1578	19930528 <--
AU 9339918	A	19931202	AU 1993-39918	19930531 <--

PRIORITY APPLN. INFO.: US 1992-891528 A 19920601 <--
OTHER SOURCE(S): MARPAT 121:255816
IT 158655-93-7P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except

adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as agrochem. fungicide)

RN 158655-93-7 CAPLUS

CN Urea, N-(4-bromophenyl)-N'-(8-hydroxy-4-oxo-3(4H)-quinazolinyl)- (CA INDEX NAME)



L5 ANSWER 32 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:270439 CAPLUS

DOCUMENT NUMBER: 120:270439

ORIGINAL REFERENCE NO.: 120:47915a,47918a

TITLE: Substituted quinazoline agrochemical fungicides

INVENTOR(S): Haley, Gregory J.

PATENT ASSIGNEE(S): American Cyanamid Co., USA

SOURCE: U.S., 14 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5270466	A	19931214	US 1992-897178	19920611 <--
US 5373011	A	19941213	US 1993-121825	19930914 <--
PRIORITY APPLN. INFO.:			US 1992-897178	A3 19920611 <--

OTHER SOURCE(S): MARPAT 120:270439

IT 154288-32-1 154288-33-2 154288-34-3
154288-35-4 154288-36-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation as agrochem. fungicide)

RN 154288-32-1 CAPLUS

CN 8-Quinazolinol, 5-chloro-4-(1-methylethoxy)- (CA INDEX NAME)



RN 154288-33-2 CAPLUS

CN 8-Quinazolinol, 5-chloro-4-propoxy- (CA INDEX NAME)



RN 154288-34-3 CAPLUS
CN 8-Quinazolinol, 5-chloro-4-ethoxy- (CA INDEX NAME)



RN 154288-35-4 CAPLUS
CN 8-Quinazolinol, 5-chloro-4-methoxy- (CA INDEX NAME)



RN 154288-36-5 CAPLUS
CN 8-Quinazolinol, 4-methoxy-5-methyl- (CA INDEX NAME)



L5 ANSWER 33 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:190736 CAPLUS
DOCUMENT NUMBER: 120:190736
ORIGINAL REFERENCE NO.: 120:33755a,33758a
TITLE: Kinetic studies of 2-(2'-haloethyl) and 2-ethenyl substituted quinazolinone alkylating agents. Acid-catalyzed dehydrohalogenation and alkylation involving a quinazolinone prototropic tautomer

AUTHOR(S): Dempcy, Robert O.; Skibo, Edward B.
CORPORATE SOURCE: Dep. Chem. Biochem., Arizona State Univ., Tempe, AZ, 85287-1604, USA
SOURCE: Bioorganic & Medicinal Chemistry (1993), 1(1), 39-43
CODEN: BMECEP; ISSN: 0968-0896
DOCUMENT TYPE: Journal
LANGUAGE: English

IT 150880-61-8 150880-62-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(acid-catalyzed tautomerization/dehydrohalogenation of 2-(2'-haloethyl) and 2-ethenyl substituted quinazolinone alkylating agents: kinetics and mechanism)

RN 150880-61-8 CAPLUS
CN 4(1H)-Quinazolinone, 2-(2-bromoethyl)-5,8-dihydroxy- (9CI) (CA INDEX NAME)



RN 150880-62-9 CAPLUS
CN 4(1H)-Quinazolinone, 2-(2-chloroethyl)-5,8-dihydroxy- (9CI) (CA INDEX NAME)



IT 150880-63-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(formation; acid-catalyzed tautomerization/dehydrohalogenation of 2-(2'-haloethyl) and 2-ethenyl substituted quinazolinone alkylating agents: kinetics and mechanism)

RN 150880-63-0 CAPLUS
CN 4(1H)-Quinazolinone, 2-ethenyl-5,8-dihydroxy- (9CI) (CA INDEX NAME)



L5 ANSWER 34 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:106627 CAPLUS
DOCUMENT NUMBER: 120:106627
ORIGINAL REFERENCE NO.: 120:18800h,18801a
TITLE: Synthesis and pharmacological evaluation of tyramine congeners containing fused heterocyclic rings
AUTHOR(S): Norcini, G.; Allievi, L.; Bertolini, G.; Casagrande, C.; Miragoli, G.; Santangelo, F.; Semeraro, C.
CORPORATE SOURCE: Zambon Group, Bresso, 20091, Italy
SOURCE: European Journal of Medicinal Chemistry (1993), 28(6), 505-11
CODEN: EJMCA5; ISSN: 0223-5234
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 120:106627
IT 152530-11-5P 152530-12-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and inotropic and antihypertensive activity of)
RN 152530-11-5 CAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 5-(2-aminoethyl)-8-hydroxy- (CA INDEX NAME)



RN 152530-12-6 CAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 5-[2-(dipropylamino)ethyl]-8-hydroxy- (CA INDEX NAME)



L5 ANSWER 35 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1993:625900 CAPLUS
DOCUMENT NUMBER: 119:225900
ORIGINAL REFERENCE NO.: 119:40323a,40326a
TITLE: Rational design of purine nucleoside phosphorylase inhibitors: design of 2-(2'-haloethyl) and 2-ethenyl substituted quinazolinone alkylating agents
AUTHOR(S): Dempcy, Robert O.; Skibo, Edward B.
CORPORATE SOURCE: Dep. Chem. Biochem., Arizona State Univ., Tempe, AZ, 85287-1604, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (1992), 2(11), 1427-34
CODEN: BMCLE8; ISSN: 0960-894X

DOCUMENT TYPE: Journal
LANGUAGE: English

IT 150880-63-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with mercaptoethanol)

RN 150880-63-0 CAPLUS

CN 4(1H)-Quinazolinone, 2-ethenyl-5,8-dihydroxy- (9CI) (CA INDEX NAME)



IT 150880-61-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reactions of)

RN 150880-61-8 CAPLUS

CN 4(1H)-Quinazolinone, 2-(2-bromoethyl)-5,8-dihydroxy- (9CI) (CA INDEX NAME)



IT 150880-62-9P 150880-64-1P 150880-65-2P
150880-66-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 150880-62-9 CAPLUS

CN 4(1H)-Quinazolinone, 2-(2-chloroethyl)-5,8-dihydroxy- (9CI) (CA INDEX NAME)



RN 150880-64-1 CAPLUS

CN 4(1H)-Quinazolinone, 5,8-dihydroxy-2-[2-[(2-hydroxyethyl)thio]ethyl]- (9CI) (CA INDEX NAME)



RN 150880-65-2 CAPLUS
CN 4(1H)-Quinazolinone-6-d, 2-(2-bromoethyl-1,1-d2)-5,8-dihydroxy- (9CI) (CA INDEX NAME)



RN 150880-66-3 CAPLUS
CN 4(1H)-Quinazolinone-6-d, 2-(ethenyl-1-d)-5,8-dihydroxy- (9CI) (CA INDEX NAME)



L5 ANSWER 36 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:505961 CAPLUS
DOCUMENT NUMBER: 115:105961
ORIGINAL REFERENCE NO.: 115:17977a,17980a
TITLE: Rational design of quinazoline-based irreversible inhibitors of human erythrocyte purine nucleoside phosphorylase
AUTHOR(S): Dempcy, Robert O.; Skibo, Edward B.
CORPORATE SOURCE: Dep. Chem., Arizona State Univ., Tempe, AZ, 85287-1604, USA
SOURCE: Biochemistry (1991), 30(34), 8480-7
CODEN: BICHAW; ISSN: 0006-2960
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 117498-06-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of, to quinone)
RN 117498-06-3 CAPLUS
CN 4(1H)-Quinazolinone, 2-(chloromethyl)-5,8-dihydroxy- (9CI) (CA INDEX NAME)



IT 135106-43-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and human erythrocyte purine nucleoside phosphorylase inhibition b)
RN 135106-43-3 CAPLUS
CN 4(1H)-Quinazolinone, 5,8-dihydroxy-6-methyl- (9CI) (CA INDEX NAME)



IT 16064-17-8P 135106-42-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and human erythrocyte purine nucleoside phosphorylase inhibition by)
RN 16064-17-8 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy- (CA INDEX NAME)



RN 135106-42-2 CAPLUS
CN 4(1H)-Quinazolinone, 5,8-dihydroxy- (9CI) (CA INDEX NAME)



L5 ANSWER 37 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:7430 CAPLUS
DOCUMENT NUMBER: 110:7430
ORIGINAL REFERENCE NO.: 110:1363a,1366a
TITLE: Studies of extended quinone methides. Design of reductive alkylating agents based on the quinazoline ring system
AUTHOR(S): Lemus, Robert H.; Skibo, Edward B.
CORPORATE SOURCE: Dep. Chem., Arizona State Univ., Tempe, AZ, 85287-1604, USA
SOURCE: Journal of Organic Chemistry (1988), 53(26), 6099-105
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 110:7430
IT 117498-05-2P 117498-06-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of, kinetics and mechanism of)
RN 117498-05-2 CAPLUS
CN 4(1H)-Quinazolinone, 2-(bromomethyl)-5,8-dihydroxy- (9CI) (CA INDEX NAME)



RN 117498-06-3 CAPLUS
CN 4(1H)-Quinazolinone, 2-(chloromethyl)-5,8-dihydroxy- (9CI) (CA INDEX NAME)



IT 117498-10-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and treatment with DDQ)
RN 117498-10-9 CAPLUS
CN 4(1H)-Quinazolinone, 5,8-dihydroxy-2-methyl-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

IT 117498-07-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 117498-07-4 CAPLUS
CN 4(1H)-Quinazolinone, 5,8-dihydroxy-2-(hydroxymethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 38 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:466400 CAPLUS
DOCUMENT NUMBER: 109:66400
ORIGINAL REFERENCE NO.: 109:10957a,10960a
TITLE: Prediction of selective bioreductive antitumor, antifolate activity using a modified ab initio method for calculating enzyme-inhibitor interaction energies
AUTHOR(S): Reynolds, Christopher A.; Richards, W. Graham; Goodford, Peter J.
CORPORATE SOURCE: Phys. Chem. Lab., Oxford, OX1 3QZ, UK
SOURCE: Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999) (1988), (4), 551-6
CODEN: JCPKBH; ISSN: 0300-9580
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 110713-95-6
RL: BIOL (Biological study)
(dihydrofolate reductase inhibitor, enzyme binding of, interaction energies of, MO prediction of antitumor activity for calculating)
RN 110713-95-6 CAPLUS
CN 4(1H)-Quinazolinone, 2-amino-5,8-dihydroxy- (9CI) (CA INDEX NAME)



L5 ANSWER 39 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:406539 CAPLUS
DOCUMENT NUMBER: 109:6539
ORIGINAL REFERENCE NO.: 109:1241a,1244a
TITLE: Quinazolin-4-one derivatives as drugs, agrochemicals, or fluorescent substances and a process for their preparation
INVENTOR(S): Terakawa, Masaaki
PATENT ASSIGNEE(S): Agency of Industrial Sciences and Technology, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62258368	A	19871110	JP 1986-52071	19860310 <--
JP 05039950	B	19930616		
PRIORITY APPLN. INFO.:			JP 1986-52071	19860310 <--

OTHER SOURCE(S): CASREACT 109:6539
IT 114882-07-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as drug, agrochem. or fluorescent substance)
RN 114882-07-4 CAPLUS
CN 4(1H)-Quinazolinone, 8-hydroxy-2-phenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 40 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:568230 CAPLUS
DOCUMENT NUMBER: 107:168230
ORIGINAL REFERENCE NO.: 107:26839a,26842a
TITLE: Introducing selectivity into dehydrofolate reductase inhibitors
AUTHOR(S): Reynolds, C. A.; Richards, W. G.; Goodford, P. J.
CORPORATE SOURCE: Phys. Chem. Lab., Univ. Oxford, Oxford, UK

SOURCE: Anti-Cancer Drug Design (1987), 1(4), 291-5
CODEN: ACDDEA; ISSN: 0266-9536
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 110713-95-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dihydrofolate reductase inhibition by, structure in relation to)
RN 110713-95-6 CAPLUS
CN 4(1H)-Quinazolinone, 2-amino-5,8-dihydroxy- (9CI) (CA INDEX NAME)



L5 ANSWER 41 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:626489 CAPLUS
DOCUMENT NUMBER: 105:226489
ORIGINAL REFERENCE NO.: 105:36575a,36578a
TITLE: 4(3H)-Quinazolinone derivatives as beta adrenergic blockers
AUTHOR(S): Nabil Aboul Enein, M.; Bibers, M.; I.Eid, Attiat; El-Kashif, H.; Moustafa, T.
CORPORATE SOURCE: Fac. Pharm., Cairo Univ., Cairo, Egypt
SOURCE: Egyptian Journal of Chemistry (1985), 27(3), 337-46
CODEN: EGJCA3; ISSN: 0367-0422
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 105:226489
IT 99071-94-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with epichlorohydrin)
RN 99071-94-0 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2,3-dimethyl- (CA INDEX NAME)



L5 ANSWER 42 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:626478 CAPLUS
DOCUMENT NUMBER: 105:226478
ORIGINAL REFERENCE NO.: 105:36571a,36574a

TITLE: Quinazolones. Part XI. Effect of substituents on Claisen rearrangement of allyloxyquinazolones

AUTHOR(S): Sinha, S. K.; Kumar, Prashant

CORPORATE SOURCE: Bihar Univ., Muzaffarpur, 842 001, India

SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1985), 24B(11), 1182-4
CODEN: IJSBDB; ISSN: 0376-4699

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 105:226478

IT 90417-38-2P 99071-94-0P 105459-48-1P
105459-51-6P 105459-52-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 90417-38-2 CAPLUS

CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



RN 99071-94-0 CAPLUS

CN 4(3H)-Quinazolinone, 8-hydroxy-2,3-dimethyl- (CA INDEX NAME)



RN 105459-48-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-ethyl-7,8-dihydroxy-3-phenyl-6-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 105459-51-6 CAPLUS

CN 4(1H)-Quinazolinone, 2-ethyl-8-hydroxy- (9CI) (CA INDEX NAME)



RN 105459-52-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-ethyl-8-hydroxy-3-phenyl- (CA INDEX NAME)



L5 ANSWER 43 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1980:41519 CAPLUS
DOCUMENT NUMBER: 92:41519
ORIGINAL REFERENCE NO.: 92:6921a,6924a
TITLE: Chemistry of salicylic acid and anthranilic acid. IV. Synthesis of 6-chloro-5-sulfamoyl- and 6-chloro-3-sulfamoylanthranilic acid derivatives
AUTHOR(S): Asakawa, Hiroyuki; Matano, Mitsuo
CORPORATE SOURCE: Chem. Res. Lab., Takeda Chem. Ind., Osaka, 532, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1979), 27(6), 1287-98
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 92:41519
IT 72290-34-7P 72290-35-8P 72290-36-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 72290-34-7 CAPLUS
CN 8-Quinazolinesulfonamide, 5-chloro-1,2,3,4-tetrahydro-4-oxo-2-phenyl- (CA INDEX NAME)



RN 72290-35-8 CAPLUS
CN 8-Quinazolinesulfonamide, 5-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo- (CA

INDEX NAME)



RN 72290-36-9 CAPLUS
CN 8-Quinazolinesulfonamide, 5-chloro-1,2,3,4-tetrahydro-2,2-dimethyl-4-oxo-
(CA INDEX NAME)



L5 ANSWER 44 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:203051 CAPLUS
DOCUMENT NUMBER: 90:203051
ORIGINAL REFERENCE NO.: 90:32289a,32292a
TITLE: Carbon-13 nuclear magnetic resonance spectra of methaqualone metabolites
AUTHOR(S): Brine, G. A.; Coleman, M. L.; Carroll, F. I.
CORPORATE SOURCE: Chem. Life Sci. Group, Research Triangle Inst., Research Triangle Park, NC, USA
SOURCE: Journal of Heterocyclic Chemistry (1979), 16(1), 25-8
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 5060-53-7
RL: PRP (Properties)
(carbon-13 NMR of)
RN 5060-53-7 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-3-(2-methylphenyl)- (CA INDEX NAME)



L5 ANSWER 45 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:86212 CAPLUS
DOCUMENT NUMBER: 90:86212
ORIGINAL REFERENCE NO.: 90:13649a,13652a
TITLE: Fourier transform 13C NMR analysis of some methaqualone metabolites
AUTHOR(S): Singh, S. P.; Kishore, Vimal; Parmar, S. S.
CORPORATE SOURCE: Dep. Physiol., Univ. North Dakota, Grand Forks, ND, USA
SOURCE: Spectroscopy Letters (1978), 11(10), 809-15
CODEN: SPLEBX; ISSN: 0038-7010
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 5060-53-7
RL: PRP (Properties)
(NMR of)
RN 5060-53-7 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-3-(2-methylphenyl)- (CA INDEX NAME)



L5 ANSWER 46 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1976:537141 CAPLUS
DOCUMENT NUMBER: 85:137141
ORIGINAL REFERENCE NO.: 85:21915a,21918a
TITLE: Blood levels of methaqualone in man following chronic therapeutic doses
AUTHOR(S): Delong, A. F.; Smyth, R. D.; Polk, A.; Nayak, R. K.; Reavey-Cantwell, N. H.
CORPORATE SOURCE: Res. Div., William H. Rorer, Inc., Fort Washington, PA, USA
SOURCE: Archives Internationales de Pharmacodynamie et de Therapie (1976), 222(2), 322-31
CODEN: AIPTAK; ISSN: 0003-9780
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 5060-53-7
RL: PROC (Process)
(separation of)

RN 5060-53-7 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-3-(2-methylphenyl)- (CA INDEX NAME)



L5 ANSWER 47 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1976:463029 CAPLUS
DOCUMENT NUMBER: 85:63029
ORIGINAL REFERENCE NO.: 85:10149a,10152a
TITLE: Novel heterocyclic ring systems: Synthesis of 1,2,7,8-tetrahydro-3H[1,3]oxazino[6,5-h]quinazoline-7-ones and 3,4,7,8,9,10-hexahydro-2H,6H[1,3]bisoxazino[5,6-f:5',6'-h]quinazoline-9-one
AUTHOR(S): Kumar, Gyanendra; Lal, B.; Singh, P.; Bhaduri, A. P.
CORPORATE SOURCE: Cent. Drug Res. Inst., Lucknow, India
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1976), 14B(2), 133-4
CODEN: IJSBDB; ISSN: 0376-4699
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 60186-46-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and Mannich reaction with paraformaldehyde and aniline)
RN 60186-46-1 CAPLUS
CN Acetamide, N-(6,8-dihydroxy-4-oxo-2-phenyl-3(4H)-quinazolinyl)- (CA INDEX NAME)



L5 ANSWER 48 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1976:173543 CAPLUS
DOCUMENT NUMBER: 84:173543
ORIGINAL REFERENCE NO.: 84:28079a,28082a
TITLE: Urinary excretion of C-hydroxy derivatives of methaqualone in man
AUTHOR(S): Burnett, David; Reynolds, Cedric N.; Wilson, Keith; Francis, J. Robert
CORPORATE SOURCE: Dep. Clin. Biochem., St. Albans City Hosp., St. Albans, UK
SOURCE: Xenobiotica (1976), 6(2), 125-34

CODEN: XENOBH; ISSN: 0049-8254
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 5060-53-7
RL: BIOL (Biological study)
(as methaqualone metabolite)
RN 5060-53-7 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-3-(2-methylphenyl)- (CA INDEX NAME)



L5 ANSWER 49 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1976:90112 CAPLUS
DOCUMENT NUMBER: 84:90112
ORIGINAL REFERENCE NO.: 84:14709a,14712a
TITLE: Heterocyclic quinones. II. Syntheses and Diels-Alder reactions of quinazolone, quinoxaline, and indolo[2,3-b]quinoxaline quinones
AUTHOR(S): Kumar, Gyanendra; Bhaduri, A. P.
CORPORATE SOURCE: Div. Med. Chem., Cent. Drug Res. Inst., Lucknow, India
SOURCE: Indian Journal of Chemistry (1975), 13(10), 1009-14
CODEN: IJOCAP; ISSN: 0019-5103
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 84:90112
IT 58351-44-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 58351-44-3 CAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 8-hydroxy-5-methoxy-3-phenyl- (CA INDEX NAME)



L5 ANSWER 50 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:578983 CAPLUS
DOCUMENT NUMBER: 83:178983
ORIGINAL REFERENCE NO.: 83:28109a,28112a
TITLE: Chloroquinazoline derivatives

AUTHOR(S): Malesani, Giorgio; Chiarelotto, Gianfranco
CORPORATE SOURCE: Ist. Chim. Farm., Univ. Padova, Padua, Italy
SOURCE: Atti - Istituto Veneto di Scienze, Lettere ed Arti, Classe di Scienze Matematiche e Naturali (1973), Volume Date 1972, 131, 9-16
CODEN: AIVLAQ; ISSN: 0365-3528
DOCUMENT TYPE: Journal
LANGUAGE: Italian
IT 57106-52-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 57106-52-2 CAPLUS
CN 4(1H)-Quinazolinone, 6,7-dichloro-8-hydroxy-5-methoxy- (9CI) (CA INDEX NAME)



L5 ANSWER 51 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:563136 CAPLUS
DOCUMENT NUMBER: 83:163136
ORIGINAL REFERENCE NO.: 83:25587a,25590a
TITLE: Medicinal chemistry of oxoquinazolines. XV. Methaqualone metabolites. Mass spectrometric investigation of the monohydroxy derivatives of methaqualone
AUTHOR(S): Bogentoft, Conny; Ericsson, Orjan; Danielsson, Bengt
CORPORATE SOURCE: Dep. Org. Pharm. Chem., Univ. Uppsala, Uppsala, Swed.
SOURCE: Acta Pharmaceutica Suecica (1974), 11(6), 513-22
CODEN: APSXAS; ISSN: 0001-6675
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 5060-53-7
RL: PRP (Properties)
(mass spectrum of)
RN 5060-53-7 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-3-(2-methylphenyl)- (CA INDEX NAME)



L5 ANSWER 52 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1975:52434 CAPLUS
DOCUMENT NUMBER: 82:52434
ORIGINAL REFERENCE NO.: 82:8335a,8338a
TITLE: Mass spectrometry-gas chromatographic determination of mecloqualone metabolites from urine extracts
AUTHOR(S): Van Boven, M.; Janssen, G.; Daenens, P.
CORPORATE SOURCE: Lab. Toxicol., Univ. Louvain, Louvain, Belg.
SOURCE: Mikrochimica Acta (1974), (4), 603-10
CODEN: MIACAQ; ISSN: 0026-3672
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 51837-89-9
RL: FORM (Formation, nonpreparative)
(formation of, as Mecloqualone metabolite of urine)
RN 51837-89-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-8-hydroxy-2-methyl- (CA INDEX NAME)



L5 ANSWER 53 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:485929 CAPLUS
DOCUMENT NUMBER: 81:85929
ORIGINAL REFERENCE NO.: 81:13591a,13594a
TITLE: Biotransformation of mecloqualone in man. Synthesis and identification of some major metabolites
AUTHOR(S): Daenens, P.; Van Boven, M.
CORPORATE SOURCE: Lab. Toxicol., Univ. Louvain, Louvain, Belg.
SOURCE: Arzneimittel-Forschung (1974), 24(2), 195-202
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 51837-89-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and formation of, as mecloqualone metabolite)
RN 51837-89-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-8-hydroxy-2-methyl- (CA INDEX NAME)



L5 ANSWER 54 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:537080 CAPLUS
DOCUMENT NUMBER: 79:137080
ORIGINAL REFERENCE NO.: 79:22217a,22220a
TITLE: Medicinal chemistry of oxoquinazolines. XIII. Methaqualone metabolites. Synthesis of eight phenolic monohydroxy derivatives of methaqualone
AUTHOR(S): Ericsson, Orjan; Bogentoft, Conny; Lindberg, Claes; Danielsson, Bengt
CORPORATE SOURCE: Fac. Pharm., Univ. Uppsala, Uppsala, Swed.
SOURCE: Acta Pharmaceutica Suecica (1973), 10(4), 257-62
CODEN: APSXAS; ISSN: 0001-6675
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 5060-53-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 5060-53-7 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-3-(2-methylphenyl)- (CA INDEX NAME)



L5 ANSWER 55 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:505174 CAPLUS
DOCUMENT NUMBER: 79:105174
ORIGINAL REFERENCE NO.: 79:17055a,17058a
TITLE: Reactions of an N-hydroxyquinazoline structurally analogous to oncogenic N-hydroxypurines
AUTHOR(S): Lee, Tzoong-Chyh; Salemnick, Gad; Brown, George Bosworth
CORPORATE SOURCE: Mem. Sloan-Kettering Cancer Cent., New York, NY, USA
SOURCE: Journal of Organic Chemistry (1973), 38(18), 3102-5
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 40919-26-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 40919-26-4 CAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 8-hydroxy- (CA INDEX NAME)



L5 ANSWER 56 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1970:477599 CAPLUS
DOCUMENT NUMBER: 73:77599
ORIGINAL REFERENCE NO.: 73:12707a,12710a
TITLE: Actinomycins. XXXV. Syntheses of actinomycins and actinomycin-like chromopeptides. VIII. Syntheses of aniso-actinocinyl peptides and aniso-actinomycins utilizing deuterium-labeled intermediates
AUTHOR(S): Lackner, Helmut
CORPORATE SOURCE: Org.-Chem. Inst., Univ. Goettingen, Goettingen, Fed. Rep. Ger.
SOURCE: Chemische Berichte (1970), 103(8), 2476-2500
CODEN: CHBEAM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: German
IT 28649-28-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 28649-28-7 CAPLUS
CN 3(2H)-Quinazolineacetic acid, 1,4-dihydro-8-hydroxy-1,7-dimethyl-4-oxo-, methyl ester (CA INDEX NAME)



L5 ANSWER 57 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1968:436066 CAPLUS
DOCUMENT NUMBER: 69:36066
ORIGINAL REFERENCE NO.: 69:6731a,6734a
TITLE: (3H)-Quinazolin-4-one derivatives with antiinflammatory activity. II. Derivatives substituted in the aromatic nucleus, and related compounds
AUTHOR(S): Maillard, Jacques; Benard, Madeleine; Vincent, Michel; Vo-Van-Tri; Jolly, Raymond; Morin, Robert; Benharkate, Mrs.; Menillet, C.
CORPORATE SOURCE: Lab. Jacques Logeais, Issy-les-Moulineaux, Fr.
SOURCE: Chim. Ther. (1967), 2(4), 231-9
CODEN: CHTQAC
DOCUMENT TYPE: Journal
LANGUAGE: French

OTHER SOURCE(S): CASREACT 69:36066
IT 16064-17-8P 19178-15-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and inflammation response to)
RN 16064-17-8 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy- (CA INDEX NAME)



RN 19178-15-5 CAPLUS
CN 4(3H)-Quinazolinone, 6,7,8-trihydroxy- (CA INDEX NAME)



L5 ANSWER 58 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1968:103738 CAPLUS
DOCUMENT NUMBER: 68:103738
ORIGINAL REFERENCE NO.: 68:20011a,20014a
TITLE: Antihypertensive 2-amino-4(3H)-quinazolinones
AUTHOR(S): Hess, Hans J.; Cronin, Timothy H.; Scriabine, Alexander
CORPORATE SOURCE: Med. Res. Lab., Chas. Pfizer and Co., Inc., Groton, CT, USA
SOURCE: Journal of Medicinal Chemistry (1968), 11(1), 130-6
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 68:103738
IT 20187-02-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antihypertensive activity of)
RN 20187-02-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-(diethylamino)-8-hydroxy-, monohydrobromide (8CI) (CA INDEX NAME)



● HBr

L5 ANSWER 59 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1966:423812 CAPLUS
DOCUMENT NUMBER: 65:23812
ORIGINAL REFERENCE NO.: 65:4450b-g
TITLE: Biotransformation of 2-methyl-3-o-tolyl-4(3H)-quinazolinone (methaqualone). II. Structure and synthesis of several renal elimination products
AUTHOR(S): Preuss, Fr. R.; Hassler, H. M.; Koepf, R.
CORPORATE SOURCE: Univ. Freiburg/Br., Germany
SOURCE: Arzneimittel-Forschung (1966), 16(3), 401-7
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: German
IT 5060-53-7P, 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-3-o-tolyl-
RL: PREP (Preparation)
(preparation of)
RN 5060-53-7 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-3-(2-methylphenyl)- (CA INDEX NAME)



L5 ANSWER 60 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1966:423811 CAPLUS
DOCUMENT NUMBER: 65:23811
ORIGINAL REFERENCE NO.: 65:4449f-h,4450a-b
TITLE: Biotransformation of 2-methyl-3-o-tolyl-4(3H)-quinazolinone (methaqualone). I. Analysis and isolation of renal elimination products and identification of several metabolites
AUTHOR(S): Preuss, Fr. R.; Hassler, H. M.; Koepf, R.
CORPORATE SOURCE: Univ. Freiburg/Br., Germany
SOURCE: Arzneimittel-Forschung (1966), 16(3), 395-401
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal

LANGUAGE: German
IT 5060-53-7
(Derived from data in the 7th Collective Formula Index (1962-1966))
RN 5060-53-7 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-3-(2-methylphenyl)- (CA INDEX NAME)



L5 ANSWER 61 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1966:423810 CAPLUS
DOCUMENT NUMBER: 65:23810
ORIGINAL REFERENCE NO.: 65:4449e-f
TITLE: Ocular penetration studies. I. Topical administration of dexamethasone
AUTHOR(S): Short, C.; Keates, R. H.; Donovan, E. F.; Wyman, M.; Murdick, P. W.
CORPORATE SOURCE: Ohio State Univ. Coll. of Med., Columbus
SOURCE: Arch. Ophthalmol. (Chicago) (1966), 75(5), 689-92
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 5060-53-7
(Derived from data in the 7th Collective Formula Index (1962-1966))
RN 5060-53-7 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-3-(2-methylphenyl)- (CA INDEX NAME)



L5 ANSWER 62 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1966:415133 CAPLUS
DOCUMENT NUMBER: 65:15133
ORIGINAL REFERENCE NO.: 65:2839g-h,2840a
TITLE: The metabolism of methaqualone
AUTHOR(S): Nowak, H.; Schorre, G.; Struller, R.
CORPORATE SOURCE: E. Merck A.-G., Darmstadt, Germany
SOURCE: Arzneimittel-Forschung (1966), 16(3), 407-11
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: German
IT 5060-53-7, 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-3-o-tolyl-

(as methaqualone metabolite)
RN 5060-53-7 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-3-(2-methylphenyl)- (CA INDEX NAME)



L5 ANSWER 63 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1964:443373 CAPLUS
DOCUMENT NUMBER: 61:43373
ORIGINAL REFERENCE NO.: 61:7566f-g
TITLE: Chemotherapeutic studies on isonicotinic hydrazone derivatives and other compounds in experimental tuberculosis
AUTHOR(S): Chatterjee, Kar K.; Mukerji, J.; Mukerji, B.
CORPORATE SOURCE: Central Drug Res. Inst., Lucknow, India
SOURCE: Journal of Scientific and Industrial Research, Section B: Physical Sciences (1961), 20C(3), 85-8
From: Biol. Abstr. 36(19), Abstr. No. 65396(1961).
CODEN: JSIBAW; ISSN: 0368-4210
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
IT 90417-38-2, 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-
(antitubercular activity of)
RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



L5 ANSWER 64 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1963:84095 CAPLUS
DOCUMENT NUMBER: 58:84095
ORIGINAL REFERENCE NO.: 58:14477e-f
TITLE: Thermal stability and mouse infectivity of vaccinia virus (Bangalore strain) and the effect of delayed administration of 8-hydroxy-4-quinazolone on pock formation in chick embryo
AUTHOR(S): Gupta, B. M.; Agarwal, Uma; Khan, S. K.
CORPORATE SOURCE: Central Drug Res. Inst., Lucknow, India
SOURCE: Indian J. Exptl. Biol. (1963), 1, 61-2
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

IT 16064-17-8, 4(3H)-Quinazolinone, 8-hydroxy-
(vaccinia virus response to)
RN 16064-17-8 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy- (CA INDEX NAME)



L5 ANSWER 65 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1963:48349 CAPLUS
DOCUMENT NUMBER: 58:48349
ORIGINAL REFERENCE NO.: 58:8254c-e
TITLE: Antiamebic action of substituted quinolines, quinaldines, quinazolines, quinazolones, chromanones, thiochromanones, diaminoalkanes, benzylamines, and cresols
AUTHOR(S): Kaushiva, B. S.
CORPORATE SOURCE: Central Drug Res. Inst., Lucknow, India
SOURCE: Ann. Biochem. Exptl. Med. (Calcutta) (1960), Suppl. 20, 493-504
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
IT 16064-17-8, 4(3H)-Quinazolinone, 8-hydroxy- 90417-39-3, 4(3H)-Quinazolinone, 8-hydroxy-3-methyl- 90915-44-9, 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy- 91351-04-1, 4(3H)-Quinazolinone, 8-hydroxy-3-propyl- 91567-04-3, 4(3H)-Quinazolinone, 3-butyl-8-hydroxy- 92437-62-2, 4(3H)-Quinazolinone, 3-benzyl-8-hydroxy-
(amebicidal action of)
RN 16064-17-8 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy- (CA INDEX NAME)



RN 90417-39-3 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-3-methyl- (CA INDEX NAME)



RN 90915-44-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy- (CA INDEX NAME)



RN 91351-04-1 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-3-propyl- (CA INDEX NAME)



RN 91567-04-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-butyl-8-hydroxy- (CA INDEX NAME)



RN 92437-62-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-3-(phenylmethyl)- (CA INDEX NAME)



L5 ANSWER 66 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1963:35031 CAPLUS
DOCUMENT NUMBER: 58:35031
ORIGINAL REFERENCE NO.: 58:6024b-c
TITLE: Effect of quinazolones, substituted hydroxyquinolines, substituted diamines, purine, and nucleoside antagonists on vaccinia virus in chick embryo
AUTHOR(S): Agarwal, Uma; Gupta, B. M.; Khan, S. K.; Clifford, I.; Chandra, K.
CORPORATE SOURCE: Central Drug Res. Inst., Lucknow
SOURCE: Journal of Scientific and Industrial Research, Section B: Physical Sciences (1962), 21C, 309-12
CODEN: JSIBAW; ISSN: 0368-4210
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
IT 95817-83-7, 4(3H)-Quinazolinone, 3-[2-(diheptylamino)ethyl]-8-hydroxy-
(effect on vaccinia virus in embryos)
RN 95817-83-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(diheptylamino)ethyl]-8-hydroxy- (CA INDEX NAME)



L5 ANSWER 67 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1962:459248 CAPLUS
DOCUMENT NUMBER: 57:59248
ORIGINAL REFERENCE NO.: 57:11799a-b
TITLE: Selective actin filament and Z-band degeneration induced by plasmocid: an electron microscopic study
AUTHOR(S): Price, Harold M.; Pease, Daniel C.; Pearson, Carl M.
CORPORATE SOURCE: Univ. of California, Los Angeles
SOURCE: Laboratory Investigation (1962), 11, 549-62
CODEN: LAINAW; ISSN: 0023-6837
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
IT 90417-38-2
(Derived from data in the 7th Collective Formula Index (1962-1966))
RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



L5 ANSWER 68 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1962:459247 CAPLUS
DOCUMENT NUMBER: 57:59247
ORIGINAL REFERENCE NO.: 57:11798i,11799a
TITLE: Inhibition of vaccinia virus pock formation by 8-hydroxy-4-quinazolone in chick embryo
AUTHOR(S): Gupta, B. M.; Khan, S. K.; Agarwal, Uma
CORPORATE SOURCE: Central Drug Res. Inst., Lucknow
SOURCE: Journal of Scientific and Industrial Research, Section B: Physical Sciences (1962), 21C, 189-90
CODEN: JSIBAW; ISSN: 0368-4210
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
IT 16064-17-8P, 4(3H)-Quinazolinone, 8-hydroxy- 94803-84-6P , 4(3H)-Quinazolinone, 8-hydroxy-7-(piperidinomethyl)-3-propyl-
RL: PREP (Preparation)
(effect on vaccinia virus pock formation)
RN 16064-17-8 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy- (CA INDEX NAME)



RN 94803-84-6 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-7-(piperidinomethyl)-3-propyl- (7CI) (CA INDEX NAME)



IT 90417-38-2, 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-
91351-04-1, 4(3H)-Quinazolinone, 8-hydroxy-3-propyl-
(toxicity to embryo)

RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



RN 91351-04-1 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-3-propyl- (CA INDEX NAME)



L5 ANSWER 69 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1962:456272 CAPLUS
DOCUMENT NUMBER: 57:56272
ORIGINAL REFERENCE NO.: 57:11194c-g
TITLE: Potential amebicides. XIII. Synthesis of Mannich bases and iodo derivatives of some 3-alkyl-8-hydroxy-4-quinazolones
AUTHOR(S): Iyer, R. N.; Dhar, M. L.
CORPORATE SOURCE: Central Drug Research Inst., Lucknow
SOURCE: Journal of Scientific & Industrial Research (1961), 20C, 175-7
CODEN: JSIRAC; ISSN: 0022-4456
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
IT 16064-17-8, 4(3H)-Quinazolinone, 8-hydroxy- (derivs.)
RN 16064-17-8 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy- (CA INDEX NAME)



IT 88565-59-7P, 4(3H)-Quinazolinone, 3-butyl-8-hydroxy-7-iodo-
90842-67-4P, 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy-7-iodo-
92287-15-5P, 4(3H)-Quinazolinone, 8-hydroxy-7-iodo-3-propyl-

92440-54-5P, 4(3H)-Quinazolinone, 8-hydroxy-3-methyl-7-(morpholinomethyl)- 92650-01-6P, 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy-7-(morpholinomethyl)- 92650-02-7P, 4(3H)-Quinazolinone, 8-hydroxy-2,3-dimethyl-7-(morpholinomethyl)- 93150-43-7P, 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy-2-methyl-7-(morpholinomethyl)- 93725-47-4P, 4(3H)-Quinazolinone, 3-butyl-8-hydroxy-7-(morpholinomethyl)- 93902-36-4P, 4(3H)-Quinazolinone, 3-butyl-8-hydroxy-7-(piperidinomethyl)- 94091-16-4P, 4(3H)-Quinazolinone, 8-hydroxy-3-methyl-7-(piperidinomethyl)- 94461-99-1P, 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy-7-(piperidinomethyl)- 94462-00-7P, 4(3H)-Quinazolinone, 8-hydroxy-2,3-dimethyl-7-(piperidinomethyl)- 94803-83-5P, 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy-2-methyl-7-(piperidinomethyl)- 94803-84-6P, 4(3H)-Quinazolinone, 8-hydroxy-7-(piperidinomethyl)-3-propyl- 94803-92-6P, 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-7-(morpholinomethyl)-3-propyl- 95364-54-8P, 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-7-(piperidinomethyl)-3-propyl- 95621-79-7P, 4(3H)-Quinazolinone, 7,7'-(1,4-piperazinediyldimethylene)bis[8-hydroxy-3-methyl- 96765-20-7P, 4(3H)-Quinazolinone, 7,7'-(1,4-piperazinediyldimethylene)bis[3-ethyl-8-hydroxy- 96765-21-8P, 4(3H)-Quinazolinone, 7,7'-(1,4-piperazinediyldimethylene)bis[8-hydroxy-2,3-dimethyl- 96931-69-0P, 4(3H)-Quinazolinone, 7,7'-(1,4-piperazinediyldimethylene)bis[8-hydroxy-3-propyl- 97645-64-2P, 4(3H)-Quinazolinone, 8-hydroxy-7-(morpholinomethyl)-3-propyl-
RL: PREP (Preparation)
(preparation of)

RN 88565-59-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-butyl-8-hydroxy-7-iodo- (CA INDEX NAME)



RN 90842-67-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy-7-iodo- (CA INDEX NAME)



RN 92287-15-5 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-7-iodo-3-propyl- (CA INDEX NAME)



RN 92440-54-5 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-3-methyl-7-(morpholinomethyl)- (7CI) (CA INDEX NAME)



RN 92650-01-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy-7-(morpholinomethyl)- (7CI) (CA INDEX NAME)



RN 92650-02-7 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2,3-dimethyl-7-(morpholinomethyl)- (7CI) (CA INDEX NAME)



RN 93150-43-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy-2-methyl-7-(morpholinomethyl)- (7CI) (CA INDEX NAME)



RN 93725-47-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-butyl-8-hydroxy-7-(morpholinomethyl)- (7CI) (CA INDEX NAME)



RN 93902-36-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-butyl-8-hydroxy-7-(piperidinomethyl)- (7CI) (CA INDEX NAME)



RN 94091-16-4 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-3-methyl-7-(piperidinomethyl)- (7CI) (CA INDEX NAME)



RN 94461-99-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy-7-(piperidinomethyl)- (7CI) (CA INDEX NAME)



RN 94462-00-7 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2,3-dimethyl-7-(piperidinomethyl)- (7CI) (CA INDEX NAME)



RN 94803-83-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy-2-methyl-7-(piperidinomethyl)- (7CI) (CA INDEX NAME)



RN 94803-84-6 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-7-(piperidinomethyl)-3-propyl- (7CI) (CA INDEX NAME)



RN 94803-92-6 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-7-(morpholinomethyl)-3-propyl- (7CI) (CA INDEX NAME)



RN 95364-54-8 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-7-(piperidinomethyl)-3-propyl- (7CI) (CA INDEX NAME)



RN 95621-79-7 CAPLUS
CN 4(3H)-Quinazolinone, 7,7'-(1,4-piperazinediyldimethylene)bis[8-hydroxy-3-methyl- (7CI) (CA INDEX NAME)



RN 96765-20-7 CAPLUS
CN 4(3H)-Quinazolinone, 7,7'-(1,4-piperazinediyldimethylene)bis[3-ethyl-8-hydroxy- (7CI) (CA INDEX NAME)



RN 96765-21-8 CAPLUS
CN 4(3H)-Quinazolinone, 7,7'-(1,4-piperazinediyldimethylene)bis[8-hydroxy-2,3-dimethyl- (7CI) (CA INDEX NAME)



RN 96931-69-0 CAPLUS
CN 4(3H)-Quinazolinone, 7,7'-(1,4-piperazinediyldimethylene)bis[8-hydroxy-3-propyl- (7CI) (CA INDEX NAME)



RN 97645-64-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-7-(morpholinomethyl)-3-propyl- (7CI) (CA INDEX NAME)



L5 ANSWER 70 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1961:87534 CAPLUS
DOCUMENT NUMBER: 55:87534
ORIGINAL REFERENCE NO.: 55:16557b-i,16558a-c
TITLE: Preparation of derivatives of 3-amino-8-hydroxy-4-quinazolone
AUTHOR(S): Dallacker, F.; Hollinger, D.; Lipp, Maria
CORPORATE SOURCE: Tech. Hochschule, Aachen, Germany
SOURCE: Monatshefte fuer Chemie (1960), 91, 1134-43
CODEN: MOCMB7; ISSN: 0026-9247
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
IT 857204-13-8, 4(3H)-Quinazolinone, 3-amino-8-hydroxy-, (derivs.)
RN 857204-13-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-8-hydroxy- (CA INDEX NAME)



IT 99358-69-7P, 4(3H)-Quinazolinone, 3-amino-8-hydroxy-2-methyl- 100061-75-4P, Urea, 1-(8-hydroxy-2-methyl-4-oxo-3(4H)-quinazolinyl)-3-methyl-2-thio- 101101-83-1P, 4(3H)-Quinazolinone, 3-amino-2-benzyl-8-hydroxy- 101878-92-6P, 4(3H)-Quinazolinone, 3-amino-8-hydroxy-2-(3-phenylpropyl)- 106377-77-9P, 4(3H)-Quinazolinone, 3-amino-8-hydroxy-2-pentyl- 106472-99-5P, 4(3H)-Quinazolinone, 3-amino-2-p-chlorobenzyl-8-hydroxy- 106739-24-6P, Urea, 1-allyl-3-(8-hydroxy-2-methyl-4-oxo-3(4H)-quinazolinyl)-2-thio-
RL: PREP (Preparation)
(preparation of)
RN 99358-69-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-8-hydroxy-2-methyl- (CA INDEX NAME)



RN 100061-75-4 CAPLUS
CN Urea, 1-(8-hydroxy-2-methyl-4-oxo-3(4H)-quinazolinyl)-3-methyl-2-thio- (6CI) (CA INDEX NAME)



RN 101101-83-1 CAPLUS
CN 4(3H)-QuinazOlinone, 3-amino-2-benzyl-8-hydroxy- (6CI) (CA INDEX NAME)



RN 101878-92-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-8-hydroxy-2-(3-phenylpropyl)- (CA INDEX NAME)



RN 106377-77-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-8-hydroxy-2-pentyl- (CA INDEX NAME)



RN 106472-99-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-2-p-chlorobenzyl-8-hydroxy- (6CI) (CA INDEX NAME)



RN 106739-24-6 CAPLUS
CN Urea, 1-allyl-3-(8-hydroxy-2-methyl-4-oxo-3(4H)-quinazolinyl)-2-thio- (6CI) (CA INDEX NAME)



L5 ANSWER 71 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1960:24720 CAPLUS
DOCUMENT NUMBER: 54:24720
ORIGINAL REFERENCE NO.: 54:4911a-b
TITLE: Amebicidal activity of some compounds related to emetine and conessine and 8-hydroxy (and 8-methoxy) quinolines and quinazolones in intestinal amebiasis of rats
AUTHOR(S): Singh, B. N.; Sharma, R.
CORPORATE SOURCE: Central Drug Research Inst., Lucknow, India
SOURCE: Chemotherapy, Proc. Symposium Lucknow (1959), Volume Date 1958 157-8
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
IT 16064-17-8, 4(3H)-Quinazolinone, 8-hydroxy- 90915-44-9, 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy-
(as amebicide)
RN 16064-17-8 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy- (CA INDEX NAME)



RN 90915-44-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy- (CA INDEX NAME)



L5 ANSWER 72 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1959:122221 CAPLUS
DOCUMENT NUMBER: 53:122221
ORIGINAL REFERENCE NO.: 53:21980d-i
TITLE: Potential amebicides. VII. Synthesis of some 3-alkyl-2-styryl-8-hydroxy-(or 8-methoxy)-4-quinazolones
AUTHOR(S): Iyer, R. N.; Dhar, M. L.
CORPORATE SOURCE: Central Drug Research Int., Lucknow
SOURCE: Journal of Scientific & Industrial Research (1958), 17C, 193-6
CODEN: JSIRAC; ISSN: 0022-4456
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
IT 857204-78-5, 4(3H)-Quinazolinone, 8-hydroxy-2-styryl- (and 3-alkyl derivs.)
RN 857204-78-5 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-(2-phenylethenyl)- (CA INDEX NAME)



IT 90417-38-2, 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (and derivs.)
RN 90417-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl- (CA INDEX NAME)



IT 99071-94-0P, 4(3H)-Quinazolinone, 8-hydroxy-2,3-dimethyl-
100615-74-5P, 4(3H)-Quinazolinone, 3-butyl-8-hydroxy-2-methyl-
100722-98-3P, 4(3H)-Quinazolinone, 8-hydroxy-3-isopentyl-2-methyl-
100722-99-4P, 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-3-pentyl-
100880-65-7P, 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-3-phenyl-
101350-81-6P, 4(3H)-Quinazolinone, 3-benzyl-8-hydroxy-2-methyl-
101444-63-7P, 4(3H)-Quinazolinone, 8-hydroxy-3-methyl-2-styryl-
101731-46-8P, 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy-2-styryl-
101731-85-5P, 4(3H)-Quinazolinone, 8-hydroxy-2-(p-methoxystyryl)-3-methyl- 102468-01-9P, 4(3H)-Quinazolinone, 8-hydroxy-3-phenyl-2-styryl- 104296-28-8P, 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy-2-methyl- 104510-24-9P, 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-3-propyl- 108668-04-8P, 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-3-phenethyl-
RL: PREP (Preparation)
(preparation of)

RN 99071-94-0 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2,3-dimethyl- (CA INDEX NAME)



RN 100615-74-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-butyl-8-hydroxy-2-methyl- (CA INDEX NAME)



RN 100722-98-3 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-3-isopentyl-2-methyl- (6CI) (CA INDEX NAME)



RN 100722-99-4 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-3-pentyl- (CA INDEX NAME)



RN 100880-65-7 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-3-phenyl- (CA INDEX NAME)



RN 101350-81-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-benzyl-8-hydroxy-2-methyl- (6CI) (CA INDEX NAME)



RN 101444-63-7 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-3-methyl-2-styryl- (6CI) (CA INDEX NAME)



RN 101731-46-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy-2-styryl- (6CI) (CA INDEX NAME)



RN 101731-85-5 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-(p-methoxystyryl)-3-methyl- (6CI) (CA INDEX NAME)



RN 102468-01-9 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-3-phenyl-2-styryl- (6CI) (CA INDEX NAME)



RN 104296-28-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy-2-methyl- (CA INDEX NAME)



RN 104510-24-9 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-3-propyl- (CA INDEX NAME)



RN 108668-04-8 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-2-methyl-3-phenethyl- (6CI) (CA INDEX NAME)



L5 ANSWER 73 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1957:51874 CAPLUS
DOCUMENT NUMBER: 51:51874
ORIGINAL REFERENCE NO.: 51:9626a-b
TITLE: Lithium derivative of sulfadiazine
AUTHOR(S): Dolique, R.; Sarfati, Ch.
CORPORATE SOURCE: Inst. Pharm. Ind., Montpelier, Fr.
SOURCE: Travaux de la Societe de Pharmacie de Montpellier (1956), 16, 123-30
CODEN: TSPMA6; ISSN: 0037-9115
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
IT 106652-95-3 108369-50-2 108719-80-8
110053-15-1 114696-22-9
(Derived from data in the 6th Collective Formula Index (1957-1961))
RN 106652-95-3 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-3-(2-piperidinoethyl)-, dihydrochloride (6CI) (CA INDEX NAME)



●2 HCl

RN 108369-50-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-dibutylaminoethyl)-8-hydroxy-, dihydrochloride (6CI) (CA INDEX NAME)



●2 HCl

RN 108719-80-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-diethylaminoethyl)-8-hydroxy-, dihydrochloride (6CI) (CA INDEX NAME)



●2 HCl

RN 110053-15-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-dipentylaminoethyl)-8-hydroxy-, dihydrochloride (6CI) (CA INDEX NAME)



●2 HCl

RN 114696-22-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-diheptylaminoethyl)-8-hydroxy-, dihydrochloride (6CI) (CA INDEX NAME)



●2 HCl

L5 ANSWER 74 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1957:51873 CAPLUS
DOCUMENT NUMBER: 51:51873
ORIGINAL REFERENCE NO.: 51:9625b-i,9626a
TITLE: Studies in potential amebicides. III. Synthesis of 4-substituted amino-8-hydroxy (and 8-methoxy) quinazolines and 3-substituted 8-hydroxy (and 8-methoxy)-4-quinazolones
AUTHOR(S): Iyer, R. N.; Anand, Nitya; Dhar, M. L.
CORPORATE SOURCE: Central Drug Research Inst., Lucknow
SOURCE: Journal of Scientific & Industrial Research (1956), 15C, 1-7
CODEN: JSIRAC; ISSN: 0022-4456
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
IT 16064-17-8, 4(3H)-Quinazolinone, 8-hydroxy- (and derivs.)
RN 16064-17-8 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy- (CA INDEX NAME)



IT 90417-39-3P, 4(3H)-Quinazolinone, 8-hydroxy-3-methyl-
90915-44-9P, 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy-
91351-04-1P, 4(3H)-Quinazolinone, 8-hydroxy-3-propyl-
91567-04-3P, 4(3H)-Quinazolinone, 3-butyl-8-hydroxy-
92437-62-2P, 4(3H)-Quinazolinone, 3-benzyl-8-hydroxy-
101012-61-7P, 4(3H)-Quinazolinone, 3-(2-bromoethyl)-8-hydroxy-
103039-18-5P, 4(3H)-Quinazolinone, 8-hydroxy-3-(2-hydroxyethyl)-
104296-29-9P, 4(3H)-Quinazolinone, 8-hydroxy-3-isopropyl-
106652-95-3P, 4(3H)-Quinazolinone, 8-hydroxy-3-(2-piperidinoethyl)-
, dihydrochloride 108369-50-2P, 4(3H)-Quinazolinone,
3-(2-dibutylaminoethyl)-8-hydroxy-, dihydrochloride 108719-80-8P
, 4(3H)-Quinazolinone, 3-(2-diethylaminoethyl)-8-hydroxy-, dihydrochloride
110053-15-1P, 4(3H)-Quinazolinone, 3-(2-dipentylaminoethyl)-8-
hydroxy-, dihydrochloride 114696-22-9P, 4(3H)-Quinazolinone,
3-(2-diheptylaminoethyl)-8-hydroxy-, dihydrochloride
RL: PREP (Preparation)
(preparation of)
RN 90417-39-3 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-3-methyl- (CA INDEX NAME)



RN 90915-44-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy- (CA INDEX NAME)



RN 91351-04-1 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-3-propyl- (CA INDEX NAME)



RN 91567-04-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-butyl-8-hydroxy- (CA INDEX NAME)



RN 92437-62-2 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-3-(phenylmethyl)- (CA INDEX NAME)



RN 101012-61-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-bromoethyl)-8-hydroxy- (CA INDEX NAME)



RN 103039-18-5 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-3-(2-hydroxyethyl)- (CA INDEX NAME)



RN 104296-29-9 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-3-isopropyl- (6CI) (CA INDEX NAME)



RN 106652-95-3 CAPLUS
CN 4(3H)-Quinazolinone, 8-hydroxy-3-(2-piperidinoethyl)-, dihydrochloride (6CI) (CA INDEX NAME)



●2 HCl

RN 108369-50-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-dibutylaminoethyl)-8-hydroxy-, dihydrochloride (6CI) (CA INDEX NAME)



●2 HCl

RN 108719-80-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-diethylaminoethyl)-8-hydroxy-, dihydrochloride (6CI) (CA INDEX NAME)



●2 HCl

RN 110053-15-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-dipentylaminoethyl)-8-hydroxy-, dihydrochloride (6CI) (CA INDEX NAME)



●2 HCl

RN 114696-22-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-diheptylaminoethyl)-8-hydroxy-, dihydrochloride (6CI) (CA INDEX NAME)



●2 HCl

L5 ANSWER 75 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1957:2326 CAPLUS
DOCUMENT NUMBER: 51:2326

ORIGINAL REFERENCE NO.: 51:538c-e
TITLE: Separation and isolation of certain urinary metabolites. Guanidine derivatives and aromatic carboxylic acids
AUTHOR(S): Lauenstein, Karl; Altman, Kurt I.
CORPORATE SOURCE: Univ. of Rochester, Rochester, NY
SOURCE: Biochimica et Biophysica Acta (1956), 21, 587-8
CODEN: BBACAQ; ISSN: 0006-3002
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 106590-24-3P, 2,4(1H,3H)-Quinazolinedione, 8-hydroxy-3-phenyl-2-thio-
RL: PREP (Preparation)
(separation and isolation from urine)
RN 106590-24-3 CAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 8-hydroxy-3-phenyl-2-thio- (6CI) (CA INDEX NAME)



L5 ANSWER 76 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1956:74251 CAPLUS
DOCUMENT NUMBER: 50:74251
ORIGINAL REFERENCE NO.: 50:14002d-i,14003a-f
TITLE: Substituted quinazolinones
INVENTOR(S): Baker, Bernard R.; Schaub, Robert E.
PATENT ASSIGNEE(S): American Cyanamid Co.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 713767		19540818	GB 1951-20948	19510905 <--

IT 858238-45-6P, 4(3H)-Quinazolinone, 5-chloro-8-hydroxy-3-[3-(3-hydroxy-2-piperidyl)acetonyl]-, dihydrochloride
RL: PREP (Preparation)
(preparation of)
RN 858238-45-6 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-8-hydroxy-3-[3-(3-hydroxy-2-piperidinyl)-2-oxopropyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

L5 ANSWER 77 OF 77 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1928:29111 CAPLUS
DOCUMENT NUMBER: 22:29111
ORIGINAL REFERENCE NO.: 22:3413f-h
TITLE: The oxidation of quinoline-8-sulfonic acid
AUTHOR(S): Sucharda, Edward
CORPORATE SOURCE: Lemberg Polytechnic
SOURCE: Kosmos (1921), Volume Date 1920-1921 18 pp.
From: Chem. Zentr. 1927, I, 3005-6
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
IT 858452-36-5P, 8-Quinazolinesulfonic acid, 4-hydroxy-
RL: PREP (Preparation)
(preparation of)
RN 858452-36-5 CAPLUS
CN 8-Quinazolinesulfonic acid, 3,4-dihydro-4-oxo- (CA INDEX NAME)



=> d l5 1-77 ibib hitstrfile registry
'HITSTRFILE' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'
'REGISTRY' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data

Warmed with 20% HCl, this forms 2-hydroxy-3-sulfobenzoic acid, C7H6O6S.2H2O, m. 213°. Ba salt, C7H4O6SBa.H2O. Na salt, with 2.5H2O. With formamide, III forms 4-hydroxy-8-sulfoquinazoline carbonizes without fusing when heated. From II was formed the Ba salt, (C8H4O5NS)2Ba, and from this in turn 7-sulfoisatin, C8H5O5NS.4H2O (II), orange-red, m. 80°, loses its H2O of crystallization at 197°. It is not identical with the thioisatin prepared by C. and A. Schliepes (Ann. 120, 1), for their Ba salt was different crystallographically and contained H2O of crystallization

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	432.15	618.96
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-61.60	-61.60

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	432.15	618.96
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-61.60	-61.60

FILE 'REGISTRY' ENTERED AT 09:58:14 ON 06 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 AUG 2008 HIGHEST RN 1038926-51-0
DICTIONARY FILE UPDATES: 5 AUG 2008 HIGHEST RN 1038926-51-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10530137\10530137b.str

chain nodes :
11 13 15 16
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
1-11 7-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
1-11 5-7 6-10 7-8 7-13 8-9 9-10
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:OH,SH

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 13:CLASS 15:CLASS 16:CLASS 17:Atom 18:Atom

L6   STRUCTURE UPLOADED

=> d l6
L6 HAS NO ANSWERS
L6   STR



G1 OH,SH

Structure attributes must be viewed using STN Express query preparation.

=> s l6 full
FULL SEARCH INITIATED 09:58:31 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   6545 TO ITERATE

100.0% PROCESSED   6545 ITERATIONS   113 ANSWERS
SEARCH TIME: 00.00.01

L7   113 SEA SSS FUL L6

=> d scan

L7   113 ANSWERS   REGISTRY COPYRIGHT 2008 ACS on STN
IN   4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-methyl-2-
     [(methylamino)methyl]-, hydrochloride (1:1)
MF   C11 H11 Cl2 N3 O2 . Cl H



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L7 113 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(1H-indazol-5-yl)-
MF C15 H8 Cl2 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 113 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4(3H)-Quinazolinone, 5,7-dichloro-3-[2-(ethylamino)ethyl]-8-hydroxy-,
hydrobromide (1:1)
MF C12 H13 Cl2 N3 O2 . Br H



● HBr

L7 113 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(4-morpholinyl)-
MF C12 H11 Cl2 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.36	797.32

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-61.60

FILE 'CAPLUS' ENTERED AT 09:58:52 ON 06 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 Aug 2008 VOL 149 ISS 6
FILE LAST UPDATED: 5 Aug 2008 (20080805/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l7
L8 5 L7

=> d l8 1-5 ibib hitstr

L8 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1469103 CAPLUS

DOCUMENT NUMBER: 148:93193
TITLE: Method using fused heterocyclic compounds for the treatment of glioma brain tumors
INVENTOR(S): Bush, Ashley
PATENT ASSIGNEE(S): Prana Biotechnology Limited, Australia
SOURCE: PCT Int. Appl., 115pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007147217	A1	20071227	WO 2007-AU876	20070622

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-815779P P 20060622
OTHER SOURCE(S): MARPAT 148:93193
IT 679797-48-9 679797-50-3 866244-23-7
866244-26-0 866244-28-2 866244-31-7
866244-37-3 866244-38-4 866244-44-2
866244-45-3 866244-46-4 866244-47-5
866244-49-7 866244-50-0 866244-51-1
866244-52-2 866244-74-8 866318-04-9
866318-06-1 866318-07-2 866318-15-2
866318-17-4 953760-11-7 953760-18-4
953760-52-6 953760-53-7 953760-54-8
953760-55-9 953760-56-0 953760-60-6
953760-61-7 953760-62-8 953760-63-9
953760-64-0 953760-65-1 953760-66-2
953760-67-3 953760-68-4 1000013-61-5
1000013-96-6 1000014-00-5 1000014-05-0
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fused heterocyclic compds. for treatment of glioma)
RN 679797-48-9 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-(4-fluorophenyl)-8-hydroxy- (CA INDEX NAME)



RN 679797-50-3 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy- (CA INDEX NAME)



RN 866244-23-7 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[2-(1-pyrrolidinyl)ethyl]-
(CA INDEX NAME)



RN 866244-26-0 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[2-(1-methyl-2-
pyrrolidinyl)ethyl]-, hydrobromide (1:2) (CA INDEX NAME)



RN 866244-28-2 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[2-(4-morpholinyl)ethyl]-
(CA INDEX NAME)



RN 866244-31-7 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(1-methylethyl)-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866244-37-3 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-[2-(diethylamino)ethyl]-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866244-38-4 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[(3-methyl-2-pyridinyl)methyl]-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866244-44-2 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 866244-45-3 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(3-pyridinyl)- (CA INDEX NAME)



RN 866244-46-4 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(4-morpholinyl)- (CA INDEX NAME)



RN 866244-47-5 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 866244-49-7 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-(1-ethyl-1H-pyrazol-5-yl)-8-hydroxy- (CA INDEX NAME)



RN 866244-50-0 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(6-methoxy-3-pyridinyl)- (CA INDEX NAME)



RN 866244-51-1 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(1-methyl-1H-benzimidazol-2-yl)- (CA INDEX NAME)



RN 866244-52-2 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(5-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 866244-74-8 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-(cyclopropylmethyl)-8-hydroxy- (CA INDEX NAME)



RN 866318-04-9 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(2-methylpropyl)- (CA INDEX NAME)



RN 866318-06-1 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(1-methylpropyl)- (CA INDEX NAME)



RN 866318-07-2 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(2-hydroxyethyl)- (CA INDEX NAME)



RN 866318-15-2 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-methyl-2-[(methylamino)methyl]- (CA INDEX NAME)



RN 866318-17-4 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-[(2,4-difluorophenyl)amino]-8-hydroxy-
(CA INDEX NAME)



RN 953760-11-7 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-3-ethyl-8-hydroxy-7-iodo- (CA INDEX NAME)



RN 953760-18-4 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-2-[(dimethylamino)methyl]-8-hydroxy-,
hydrobromide (1:1) (CA INDEX NAME)



RN 953760-52-6 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(imidazo[1,2-a]pyridin-2-
ylmethyl)- (CA INDEX NAME)



RN 953760-53-7 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 953760-54-8 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 953760-55-9 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[(1-methyl-1H-imidazol-2-yl)methyl]- (CA INDEX NAME)



RN 953760-56-0 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(1H-indazol-5-yl)- (CA INDEX NAME)



RN 953760-60-6 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(imidazo[1,2-a]pyridin-7-ylmethyl)- (CA INDEX NAME)



RN 953760-61-7 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[[(2S)-1-methyl-2-pyrrolidinyl]methyl]-, hydrobromide (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HBr

RN 953760-62-8 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(2-thiazolylmethyl)- (CA INDEX NAME)



RN 953760-63-9 CAPLUS

CN 3(4H)-Quinazolinebutanoic acid, 5,7-dichloro-8-hydroxy-4-oxo- (CA INDEX NAME)



RN 953760-64-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-benzothiazolylmethyl)-5,7-dichloro-8-hydroxy- (CA INDEX NAME)



RN 953760-65-1 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[2-[(4-pyridinylmethyl)amino]ethyl]-, hydrobromide (1:2) (CA INDEX NAME)



●2 HBr

RN 953760-66-2 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-(cyclopropylmethyl)-2-[(dimethylamino)methyl]-8-hydroxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 953760-67-3 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-2-[(dimethylamino)methyl]-3-ethyl-8-hydroxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 953760-68-4 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-2-[(dimethylamino)methyl]-8-hydroxy-3-methyl-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 1000013-61-5 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-2-[(diethylamino)methyl]-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 1000013-96-6 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 1000014-00-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-(1H-benzimidazol-2-ylmethyl)-5,7-dichloro-8-hydroxy- (CA INDEX NAME)



RN 1000014-05-0 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-(3,5-dimethyl-4-isoxazolyl)-8-hydroxy- (CA INDEX NAME)



IT 866244-40-8 866244-43-1 866244-53-3

866244-54-4 866244-55-5 953760-12-8
953760-57-1 953760-58-2 953760-59-3
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fused heterocyclic compds. for treatment of glioma)

RN 866244-40-8 CAPLUS
CN 4(3H)-Quinazolinone, 3,3'-[2,6-pyridinediylbis(methylene)]bis[5,7-dichloro-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866244-43-1 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(5-methyl-2-thiazolyl)- (CA INDEX NAME)



RN 866244-53-3 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-(5-chloro-2-pyridinyl)-8-hydroxy- (CA INDEX NAME)



RN 866244-54-4 CAPLUS

CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(1-piperidinyl)- (CA INDEX NAME)



RN 866244-55-5 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 953760-12-8 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-3-(cyclopropylmethyl)-8-hydroxy-7-iodo- (CA INDEX NAME)



RN 953760-57-1 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 5-(5,7-dichloro-8-hydroxy-4-oxo-3(4H)-quinazolinyl)- (CA INDEX NAME)



RN 953760-58-2 CAPLUS
CN 3(4H)-Quinazolineacetic acid, 5,7-dichloro-8-hydroxy-4-oxo- (CA INDEX NAME)



RN 953760-59-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-[(2-amino-4-pyridinyl)methyl]-5,7-dichloro-8-hydroxy- (CA INDEX NAME)



IT 1000013-63-7
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fused heterocyclic compds. for treatment of glioma)
RN 1000013-63-7 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-8-hydroxy-7-iodo-3-propyl- (CA INDEX NAME)



IT 866244-27-1 866244-29-3 866244-30-6
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fused heterocyclic compds. for treatment of glioma)
RN 866244-27-1 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 866244-29-3 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[(2-methyl-4-thiazolyl)methyl]- (CA INDEX NAME)



RN 866244-30-6 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-[(3,5-dimethyl-4-isoxazolyl)methyl]-8-hydroxy- (CA INDEX NAME)



IT 866244-39-5 866244-48-6 866244-56-6
866244-62-4 866318-05-0 866318-12-9
953760-13-9 953760-34-4 953760-69-5
1000013-70-6 1000013-71-7 1000013-81-9
1000013-97-7 1000013-98-8 1000013-99-9
1000014-02-7 1000014-03-8 1000014-04-9
1000014-06-1 1000014-07-2
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fused heterocyclic compds. for treatment of glioma)
RN 866244-39-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-bromobutyl)-5,7-dichloro-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866244-48-6 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(4-piperidinylmethyl)- (CA INDEX NAME)



RN 866244-56-6 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-2-[(methylamino)methyl]-3-propyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 866244-62-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5,7-dichloro-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866318-05-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-butyl-5,7-dichloro-8-hydroxy- (CA INDEX NAME)



RN 866318-12-9 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-ethyl-8-hydroxy- (CA INDEX NAME)



RN 953760-13-9 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-8-hydroxy-7-iodo-3-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 953760-34-4 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-8-hydroxy-7-iodo-3-(3-pyridinyl)- (CA INDEX NAME)



RN 953760-69-5 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-2-[(dimethylamino)methyl]-8-hydroxy-3-(2-methylpropyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 1000013-70-6 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-pentyl- (CA INDEX NAME)



RN 1000013-71-7 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(2-methylbutyl)- (CA INDEX NAME)



RN 1000013-81-9 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-(5,7-dichloro-8-hydroxy-4-oxo-3(4H)-quinazolinyl)ethyl]- (CA INDEX NAME)



RN 1000013-97-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-benzothiazolyl)-5,7-dichloro-8-hydroxy- (CA INDEX NAME)



RN 1000013-98-8 CAPLUS
CN Benzenemethanesulfonamide, 4-(5,7-dichloro-8-hydroxy-4-oxo-3(4H)-quinazolinyl)-N-methyl- (CA INDEX NAME)



RN 1000013-99-9 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-[2-(1,3-dihydro-2H-isoindol-2-yl)ethyl]-8-hydroxy- (CA INDEX NAME)



RN 1000014-02-7 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 1000014-03-8 CAPLUS
CN 3(4H)-Quinazolineacetamide, 5,7-dichloro-N,N-diethyl-8-hydroxy-4-oxo- (CA INDEX NAME)



RN 1000014-04-9 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-[2-(ethylamino)ethyl]-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 1000014-06-1 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-[2-(cyclopropylamino)ethyl]-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 1000014-07-2 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-(3,4-dimethyl-5-isoxazolyl)-8-hydroxy-
(CA INDEX NAME)



IT 679797-49-0 866244-25-9 866244-32-8
866244-33-9 866244-64-6 953760-31-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(fused heterocyclic compds. for treatment of glioma)
RN 679797-49-0 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-cyclopropyl-8-hydroxy- (CA INDEX
NAME)



RN 866244-25-9 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-(cyclopropylmethyl)-8-hydroxy-,
hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866244-32-8 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-propyl-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866244-33-9 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(2-methylpropyl)-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866244-64-6 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-[(2,4-difluorophenyl)amino]-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 953760-31-1 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-methyl-2-[(methylamino)methyl]-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

IT 866244-42-0 953760-39-9 1000013-44-4
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fused heterocyclic compds. for treatment of glioma)
RN 866244-42-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-buten-1-yl)-5,7-dichloro-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 953760-39-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy-5,7-diiodo- (CA INDEX NAME)



RN 1000013-44-4 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-cyclopropyl-8-hydroxy-2-[(methylamino)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1207662 CAPLUS
DOCUMENT NUMBER: 147:480413
TITLE: Method using PB-1033 and related compounds for the treatment of age-related macular degeneration (AMD)
INVENTOR(S): Bush, Ashley; Masters, Colin Louis
PATENT ASSIGNEE(S): Prana Biotechnology Ltd, Australia
SOURCE: PCT Int. Appl., 109pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007118276	A1	20071025	WO 2007-AU490	20070413

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-792278P P 20060414
OTHER SOURCE(S): MARPAT 147:480413
IT 866244-23-7 866244-27-1 866244-29-3
866244-30-6 866244-31-7 866244-44-2
866244-49-7 866244-50-0 866244-52-2
866244-74-8 866318-06-1 866318-17-4
953760-09-3 953760-11-7 953760-12-8
953760-18-4 953760-31-1 953760-52-6
953760-53-7 953760-54-8 953760-55-9
953760-56-0 953760-58-2 953760-60-6
953760-61-7 953760-62-8 953760-63-9
953760-64-0 953760-65-1 953760-66-2
953760-67-3 953760-68-4
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PB-1033 and related compds. for treatment of age-related macular degeneration)
RN 866244-23-7 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 866244-27-1 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 866244-29-3 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[(2-methyl-4-thiazolyl)methyl]- (CA INDEX NAME)



RN 866244-30-6 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-[(3,5-dimethyl-4-isoxazolyl)methyl]-8-hydroxy- (CA INDEX NAME)



RN 866244-31-7 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(1-methylethyl)-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866244-44-2 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 866244-49-7 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-(1-ethyl-1H-pyrazol-5-yl)-8-hydroxy- (CA INDEX NAME)



RN 866244-50-0 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(6-methoxy-3-pyridinyl)-
(CA INDEX NAME)



RN 866244-52-2 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(5-methyl-2-pyridinyl)- (CA
INDEX NAME)



RN 866244-74-8 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-(cyclopropylmethyl)-8-hydroxy- (CA
INDEX NAME)



RN 866318-06-1 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(1-methylpropyl)- (CA INDEX
NAME)



RN 866318-17-4 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-[(2,4-difluorophenyl)amino]-8-hydroxy- (CA INDEX NAME)



RN 953760-09-3 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-2-[(diethylamino)methyl]-8-hydroxy- (CA INDEX NAME)



RN 953760-11-7 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-3-ethyl-8-hydroxy-7-iodo- (CA INDEX NAME)



RN 953760-12-8 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-3-(cyclopropylmethyl)-8-hydroxy-7-iodo- (CA INDEX NAME)



RN 953760-18-4 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-2-[(dimethylamino)methyl]-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 953760-31-1 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-methyl-2-[(methylamino)methyl]-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 953760-52-6 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(imidazo[1,2-a]pyridin-2-ylmethyl)- (CA INDEX NAME)



RN 953760-53-7 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 953760-54-8 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 953760-55-9 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[(1-methyl-1H-imidazol-2-yl)methyl]- (CA INDEX NAME)



RN 953760-56-0 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(1H-indazol-5-yl)- (CA INDEX NAME)



RN 953760-58-2 CAPLUS
CN 3(4H)-Quinazolineacetic acid, 5,7-dichloro-8-hydroxy-4-oxo- (CA INDEX NAME)



RN 953760-60-6 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(imidazo[1,2-a]pyridin-7-ylmethyl)- (CA INDEX NAME)



RN 953760-61-7 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[[(2S)-1-methyl-2-pyrrolidinyl]methyl]-, hydrobromide (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HBr

RN 953760-62-8 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(2-thiazolylmethyl)- (CA INDEX NAME)



RN 953760-63-9 CAPLUS
CN 3(4H)-Quinazolinebutanoic acid, 5,7-dichloro-8-hydroxy-4-oxo- (CA INDEX NAME)



RN 953760-64-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-benzothiazolylmethyl)-5,7-dichloro-8-hydroxy- (CA INDEX NAME)



RN 953760-65-1 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[2-[(4-pyridinylmethyl)amino]ethyl]-, hydrobromide (1:2) (CA INDEX NAME)



● 2 HBr

RN 953760-66-2 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-(cyclopropylmethyl)-2-[(dimethylamino)methyl]-8-hydroxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 953760-67-3 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-2-[(dimethylamino)methyl]-3-ethyl-8-hydroxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 953760-68-4 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-2-[(dimethylamino)methyl]-8-hydroxy-3-methyl-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

IT 866244-40-8 953760-57-1 953760-59-3
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PB-1033 and related compds. for treatment of age-related macular degeneration)
RN 866244-40-8 CAPLUS
CN 4(3H)-Quinazolinone, 3,3'-[2,6-pyridinediylbis(methylene)]bis[5,7-dichloro-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 953760-57-1 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 5-(5,7-dichloro-8-hydroxy-4-oxo-3(4H)-quinazolinyl)- (CA INDEX NAME)



RN 953760-59-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-[(2-amino-4-pyridinyl)methyl]-5,7-dichloro-8-

hydroxy- (CA INDEX NAME)



IT 866244-42-0 866318-10-7 866318-12-9
953760-13-9 953760-34-4 953760-39-9
953760-69-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PB-1033 and related compds. for treatment of age-related macular degeneration)
RN 866244-42-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-buten-1-yl)-5,7-dichloro-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)





RN 866318-10-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-bromobutyl)-5,7-dichloro-8-hydroxy- (CA INDEX NAME)

RN 866318-12-9 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-ethyl-8-hydroxy- (CA INDEX NAME)



RN 953760-13-9 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-8-hydroxy-7-iodo-3-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 953760-34-4 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-8-hydroxy-7-iodo-3-(3-pyridinyl)- (CA INDEX NAME)



RN 953760-39-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-ethyl-8-hydroxy-5,7-diiodo- (CA INDEX NAME)



RN 953760-69-5 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-2-[(dimethylamino)methyl]-8-hydroxy-3-(2-methylpropyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1103759 CAPLUS
DOCUMENT NUMBER: 143:387053
TITLE: Preparation of quinazoline derivatives as neurologically-active compounds for the treatment of Alzheimer's disease
INVENTOR(S): Kok, Gaik Beng; Leung, Brenda Kwan Yi
PATENT ASSIGNEE(S): Prana Biotechnology Limited, Australia
SOURCE: PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005095360	A1	20051013	WO 2005-AU477	20050401
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005229161	A1	20051013	AU 2005-229161	20050401
CA 2563038	A1	20051013	CA 2005-2563038	20050401
EP 1737831	A1	20070103	EP 2005-714346	20050401
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
BR 2005008183	A	20070807	BR 2005-8183	20050401
CN 101018772	A	20070815	CN 2005-80018043	20050401
JP 2007530601	T	20071101	JP 2007-505341	20050401
MX 2006PA11236	A	20070116	MX 2006-PA11236	20060929
IN 2006KN03178	A	20070608	IN 2006-KN3178	20061031
US 20080119470	A1	20080522	US 2007-547056	20071113
PRIORITY APPLN. INFO.:			AU 2004-901802	A 20040402
			AU 2004-901804	A 20040402
			AU 2004-907359	A 20041224
			WO 2005-AU477	W 20050401

OTHER SOURCE(S): CASREACT 143:387053; MARPAT 143:387053
IT 866244-23-7P 866244-25-9P 866244-27-1P
866244-29-3P 866244-30-6P 866244-31-7P
866244-32-8P 866244-35-1P 866244-38-4P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazoline derivs. as neurol.-active compds. for treatment of Alzheimer's disease)
RN 866244-23-7 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 866244-25-9 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-(cyclopropylmethyl)-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866244-27-1 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 866244-29-3 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[(2-methyl-4-thiazolyl)methyl]- (CA INDEX NAME)



RN 866244-30-6 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-[(3,5-dimethyl-4-isoxazolyl)methyl]-8-hydroxy- (CA INDEX NAME)



RN 866244-31-7 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(1-methylethyl)-, hydrobromide (1:1) (CA INDEX NAME)



RN 866244-32-8 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-propyl-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866244-35-1 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(1-methylpropyl)-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866244-38-4 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[(3-methyl-2-pyridinyl)methyl]-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

IT 866244-26-0P 866244-28-2P 866244-33-9P
866244-34-0P 866244-36-2P 866244-37-3P
866244-39-5P 866244-40-8P 866244-41-9P
866244-42-0P 866244-43-1P 866244-44-2P
866244-45-3P 866244-46-4P 866244-47-5P
866244-48-6P 866244-49-7P 866244-50-0P
866244-51-1P 866244-52-2P 866244-53-3P
866244-54-4P 866244-55-5P 866244-56-6P
866244-57-7P 866244-62-4P 866244-64-6P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazoline derivs. as neurol.-active compds. for treatment of Alzheimer's disease)

RN 866244-26-0 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[2-(1-methyl-2-pyrrolidinyl)ethyl]-, hydrobromide (1:2) (CA INDEX NAME)



●2 HBr

RN 866244-28-2 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 866244-33-9 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(2-methylpropyl)-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866244-34-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-butyl-5,7-dichloro-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866244-36-2 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(2-hydroxyethyl)-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866244-37-3 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-[2-(diethylamino)ethyl]-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866244-39-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-bromobutyl)-5,7-dichloro-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866244-40-8 CAPLUS
CN 4(3H)-Quinazolinone, 3,3'-[2,6-pyridinediylbis(methylene)]bis[5,7-dichloro-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866244-41-9 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-ethyl-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866244-42-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-buten-1-yl)-5,7-dichloro-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866244-43-1 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(5-methyl-2-thiazolyl)- (CA INDEX NAME)



RN 866244-44-2 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 866244-45-3 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(3-pyridinyl)- (CA INDEX NAME)



RN 866244-46-4 CAPLUS

CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(4-morpholinyl)- (CA INDEX NAME)



RN 866244-47-5 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 866244-48-6 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(4-piperidinylmethyl)- (CA INDEX NAME)



RN 866244-49-7 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-(1-ethyl-1H-pyrazol-5-yl)-8-hydroxy- (CA INDEX NAME)



RN 866244-50-0 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(6-methoxy-3-pyridinyl)- (CA INDEX NAME)



RN 866244-51-1 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(1-methyl-1H-benzimidazol-2-yl)- (CA INDEX NAME)



RN 866244-52-2 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(5-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 866244-53-3 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-(5-chloro-2-pyridinyl)-8-hydroxy- (CA INDEX NAME)



RN 866244-54-4 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(1-piperidinyl)- (CA INDEX NAME)



RN 866244-55-5 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 866244-56-6 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-2-[(methylamino)methyl]-3-propyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 866244-57-7 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy-3-methyl-2-[(methylamino)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 866244-62-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5,7-dichloro-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

RN 866244-64-6 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-[(2,4-difluorophenyl)amino]-8-hydroxy-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

IT 866244-74-8P 866244-93-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinazoline derivs. as neurol.-active compds. for treatment of Alzheimer's disease)
RN 866244-74-8 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-(cyclopropylmethyl)-8-hydroxy- (CA INDEX NAME)



RN 866244-93-1 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-2-(chloromethyl)-8-hydroxy-3-propyl- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:308423 CAPLUS
DOCUMENT NUMBER: 140:332510
TITLE: Neurologically active heterocyclic compounds, their preparation, and their therapeutic use
INVENTOR(S): Kok, Gaik Beng; Leung, Brenda Kwan Yi; Gautier, Elisabeth Colette Louise; Barnham, Kevin Jeffrey
PATENT ASSIGNEE(S): Prana Biotechnology Limited, Australia
SOURCE: PCT Int. Appl., 183 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031161	A1	20040415	WO 2003-AU1303	20031003
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2500952	A1	20040415	CA 2003-2500952	20031003
AU 2003265740	A1	20040423	AU 2003-265740	20031003
EP 1558585	A1	20050803	EP 2003-798831	20031003
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015008	A	20050809	BR 2003-15008	20031003
CN 1720238	A	20060111	CN 2003-80105290	20031003
JP 2006508929	T	20060316	JP 2004-540379	20031003
NZ 539211	A	20080530	NZ 2003-539211	20031003
IN 2005KN00785	A	20060609	IN 2005-KN785	20050502
US 20060167000	A1	20060727	US 2005-530137	20051003

PRIORITY APPLN. INFO.:		
AU 2002-951864	A	20021004
AU 2002-951865	A	20021004
AU 2002-951866	A	20021004
AU 2002-951868	A	20021004
WO 2003-AU1303	W	20031003

OTHER SOURCE(S): MARPAT 140:332510
IT 679797-49-0P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP

(Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(neurol. active heterocyclic compds., preparation, and therapeutic use)
RN 679797-49-0 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-cyclopropyl-8-hydroxy- (CA INDEX NAME)



IT 679797-48-9P 679797-50-3P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(neurol. active heterocyclic compds., preparation, and therapeutic use)
RN 679797-48-9 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-3-(4-fluorophenyl)-8-hydroxy- (CA INDEX NAME)



RN 679797-50-3 CAPLUS
CN 4(3H)-Quinazolinone, 5,7-dichloro-8-hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:578983 CAPLUS
DOCUMENT NUMBER: 83:178983
ORIGINAL REFERENCE NO.: 83:28109a,28112a
TITLE: Chloroquinazoline derivatives
AUTHOR(S): Malesani, Giorgio; Chiarelotto, Gianfranco
CORPORATE SOURCE: Ist. Chim. Farm., Univ. Padova, Padua, Italy

SOURCE: Atti - Istituto Veneto di Scienze, Lettere ed Arti, Classe di Scienze Matematiche e Naturali (1973), Volume Date 1972, 131, 9-16
CODEN: AIVLAQ; ISSN: 0365-3528
DOCUMENT TYPE: Journal
LANGUAGE: Italian
IT 57106-52-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 57106-52-2 CAPLUS
CN 4(1H)-Quinazolinone, 6,7-dichloro-8-hydroxy-5-methoxy- (9CI) (CA INDEX NAME)



=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	20.67	817.99
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-61.60

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:00:59 ON 06 AUG 2008